预约演示
更新于：2026-06-03
Ivermectin
伊维菌素
更新于：2026-06-03
概要
基本信息
简介伊维菌素是一种小分子药物，作为谷氨酸门控氯离子通道的调节剂起作用，这一作用构成了其药理活性的基础。该药物于 1996 年 11 月获得 FDA 批准，其开发可归功于 Merck Sharp & Dohme Corp 的卓越努力。在众多治疗应用中，Ivermectin 用于治疗寄生虫感染，包括疥疮、虱子感染、丝虫象皮病和不同类型的蠕虫病。此外，它已证明在治疗红斑痤疮方面具有疗效，红斑痤疮是一种以炎症为特征的令人不安的皮肤病症。伊维菌素的广谱抗寄生虫作用使其成为旨在控制和消除高流行地区寄生虫感染的大规模药物管理计划的优秀候选者。 |
药物类型 小分子化药 |
别名 mdc-STM、CD-5024、K-237 + [13] |
靶点 |
作用方式 调节剂 |
作用机制 谷氨酸门控氯离子通道调节剂 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C47H72O14 |
InChIKeyVARHUCVRRNANBD-PVVXTEPVSA-N |
CAS号70209-81-3 |
关联
315
项与 伊维菌素 相关的临床试验NCT03553615
Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis
This pilot trial studies how well a novel oral therapeutic agent performs to treat patients with atopic dermatitis, particularly facial dermatitis.
开始日期2030-12-01 |
申办/合作机构 |
NCT07487805
Ivermectin Combined With Immune-Checkpoint Inhibition in Cancer (ICONIC)
Public awareness of ivermectin's purported anticancer properties has led to widespread off-label use. In a 2023 cross-sectional study in Loja, Ecuador, 19% of respondents reported using ivermectin as an adjunct to cancer treatment. However, clinical data remain virtually absent. To date, only one partially reported human study has investigated ivermectin in combination with anti-PD-1 therapy in patients with metastatic triple-negative breast cancer. Among the first nine treated patients, no treatment-related serious adverse events were observed, and the study remains ongoing.
Despite this growing interest, ivermectin's off-label use carries risks. For instance, Gilene et al. described a case of severe neurotoxicity in a patient with metastatic osteosarcoma receiving regorafenib, likely due to a pharmacokinetic interaction through CYP3A49. Moreover, the potential impact of ivermectin on the gut microbiome-a key modulator of immune checkpoint inhibitor (ICI) immunotherapy success or failure efficacy-remains poorly understood. As antibiotic exposure has been linked to diminished immunotherapy outcomes, ivermectin's antibiotic properties raise legitimate concerns about possible microbiome disruption. However, variables such as ivermectin dose, the duration of exposure, and the type of immunotherapy are each variables that remain poorly studied.
Taken together, these data underscore the urgency to prospectively evaluate ivermectin's immunologic effects in patients with cancer treated ICIs. Given ivermectin's wide availability, affordability, and public interest, rigorous clinical testing is crucial to determine whether it enhances-or potentially compromises-anticancer immunity while simultaneously assessing its safety to provide guidance for clinicians and patients.
This study will investigate the safety, pharmacodynamic effects, and potential for dose-responsive immune modulation of ivermectin given concurrently with immune checkpoint inhibitor therapy in adult subjects with solid tumors.
Despite this growing interest, ivermectin's off-label use carries risks. For instance, Gilene et al. described a case of severe neurotoxicity in a patient with metastatic osteosarcoma receiving regorafenib, likely due to a pharmacokinetic interaction through CYP3A49. Moreover, the potential impact of ivermectin on the gut microbiome-a key modulator of immune checkpoint inhibitor (ICI) immunotherapy success or failure efficacy-remains poorly understood. As antibiotic exposure has been linked to diminished immunotherapy outcomes, ivermectin's antibiotic properties raise legitimate concerns about possible microbiome disruption. However, variables such as ivermectin dose, the duration of exposure, and the type of immunotherapy are each variables that remain poorly studied.
Taken together, these data underscore the urgency to prospectively evaluate ivermectin's immunologic effects in patients with cancer treated ICIs. Given ivermectin's wide availability, affordability, and public interest, rigorous clinical testing is crucial to determine whether it enhances-or potentially compromises-anticancer immunity while simultaneously assessing its safety to provide guidance for clinicians and patients.
This study will investigate the safety, pharmacodynamic effects, and potential for dose-responsive immune modulation of ivermectin given concurrently with immune checkpoint inhibitor therapy in adult subjects with solid tumors.
开始日期2026-07-01 |
申办/合作机构 |
NCT06918665
HEALTH Trial - Healthy Adult Evaluation of Ivermectin Bioequivalence: Infant Versus Standard Formulation
This is a clinical trial to compare two formulations of the drug ivermectin: the standard 3mg tablet formulation versus a newly developed infant formula preparation. The goal of the trial is to determine if the new formulation functions in the same way, tastes the same and causes no new side effects. The trial will involve 52 participants who will be healthy adult volunteers. The participants will receive both formulations - the order they receive each formulation will be assigned randomly (similar to the toss of a coin).
开始日期2026-07-01 |
申办/合作机构 |
100 项与 伊维菌素 相关的临床结果
登录后查看更多信息
100 项与 伊维菌素 相关的转化医学
登录后查看更多信息
100 项与 伊维菌素 相关的专利（医药）
登录后查看更多信息
6,375
项与 伊维菌素 相关的文献（医药）2026-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT
Treatment of redness in rosacea with potassium–titanyl-phosphate (KTP) 532 nm laser with and without topical 1% ivermectin cream: a randomized split-face trial
Article
作者: Heidemeyer, Kristine ; Junge, Alexandra ; Lehmann, Mathias ; Bossart, Simon ; Yawalkar, Nikhil ; Feldmeyer, Laurence ; Cazzaniga, Simone ; Seyed Jafari, S. Morteza
CLINICAL TRIAL REGISTER:
clinicalTrials.gov (NCT06033352).
2026-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT
From signal to strategy: a disproportionality analysis of dupilumab-associated rosacea in FAERS with a summary of reported clinical cases
Review
作者: Yang, Xuefan ; Ruan, Dandan ; Chen, Xiang ; Li, Sitong ; Lin, Jiacheng ; Qiu, Xinlan ; Li, Jiaqi ; Ju, Qiang ; Mo, Xiaohui
PURPOSE:
Emerging evidence suggests rosacea as a recognizable adverse event during dupilumab therapy. This study aimed to investigate the potential association between dupilumab and rosacea using pharmacovigilance data and to characterize the clinical features of dupilumab-associated rosacea (DAR) through a review of reported cases.
MATERIALS AND METHODS:
We utilized the FDA Adverse Event Reporting System (FAERS) database (2017-2024) to identify disproportionality signals using four methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Information Component (IC), and Empirical Bayesian Geometric Mean (EBGM). To contextualize these findings, we performed a focused narrative review of 8 publications comprising 10 DAR cases with extractable individual data.
RESULTS:
A significant disproportionality signal was identified across all four methods (ROR 3.873; PRR 3.872; IC 1.865 with IC025 1.653; EBGM 3.642), with reports predominantly in adults and females. In the case review, a consistent phenotype emerged: papulopustules on persistent centrofacial erythema with frequent burning; facial predominance with occasional extension to neck, scalp, or upper trunk; frequent Demodex detection by scraping, KOH, or in vivo imaging; and occasional granulomatous histology. Onset ranged from approximately 2 weeks to 21 months, including one post-discontinuation case. Most patients improved with rosacea-directed therapy (topical ivermectin or metronidazole; anti-inflammatory-dose doxycycline). However, dechallenge or rechallenge patterns and the need for dose-interval extension, temporary interruption, or switching biologic (e.g., lebrikizumab, upadacitinib) in a subset support a drug-related pattern at the reporting level.
CONCLUSIONS:
DAR represents a distinct clinical entity from dupilumab-associated head and neck dermatitis, which is eczematous and typically responds to antifungals or calcineurin inhibitors. While disproportionality signals indicate association rather than incidence or causality and are subject to reporting bias, clinicians should be aware of this potential adverse event to ensure appropriate management.
2026-10-01·PARASITOLOGY INTERNATIONAL
Susceptibility of Rhipicephalus microplus tick populations from western Pará to different acaricides
Article
作者: Peleja, Poliana Leão ; Klafke, Guilherme M ; Sousa, Ana Beatriz Barbosa ; Bianchi, Daniela ; Minervino, Antonio Humberto Hamad
The continuous and inappropriate use of acaricides for the control of the cattle tick has led to the emergence of populations resistant to different acaricides. Considering the scarcity of studies in western Pará, the aim of this study was to evaluate the susceptibility of Rhipicephalus microplus populations to doramectin, ivermectin, and amitraz. Engorged females were collected from cattle originating from Novo Progresso, Uruará, Rurópolis, and Mojuí dos Campos and incubated in batches until oviposition. The larvae obtained were then used in the Larval Packet Test (LPT) and the Porto Alegre (POA) susceptible reference strain was tested concurrently using the same impregnated paper packets. Lethal concentrations (LC₅₀ and LC₉₅) were estimated using PROBIT analysis and resistance ratios (RR₅₀) were calculated. Resistance to ivermectin was detected in Novo Progresso (RR₅₀ = 3.1), while Uruará and Mojuí dos Campos were susceptible. For doramectin, incipient resistance was detected in Novo Progresso (RR₅₀ = 1.71) while Rurópolis and Uruará were susceptible. Regarding amitraz, Mojuí dos Campos tick population was resistant (RR₅₀ = 9.66), while Novo Progresso was susceptible to this acaricide. The present study reveals heterogeneous susceptibility profiles of R. microplus populations from western Pará to amitraz, ivermectin, and doramectin. To the best of our knowledge, this is the first study to evaluate the susceptibility of R. microplus populations to macrocyclic lactones from western Pará.
250
项与 伊维菌素 相关的新闻（医药）2026-05-31
THE LANCET Infectious Diseases. Volume 26Number 1
柳叶刀传染病学 26卷 1期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
Urgent need for infection prevention and control in prisons
监狱中感染预防和控制的迫切需求
The Lancet Infectious Diseases
The Lancet Infectious Diseases Vol 26(1):p1
COMMENT（述评）
2
Now is the time to integrate serology into routine infectious disease surveillance
现在是时候将血清学纳入常规传染病监测了
Simon Cauchemez
The Lancet Infectious Diseases Vol 26(1):p2
3
Reassessing sotrovimab's role in COVID-19: insights and implications
重新评估索托维单抗在新冠肺炎治疗中的作用：见解与启示
Daniele Focosi,Fabrizio Maggi
The Lancet Infectious Diseases Vol 26(1):p3
4
Shaping opportunities for future clinical trials in tuberculosis
为未来结核病临床试验创造机会
Ivan Noreña,Beno Mbeya,Joanitah Nalunjogi,Ombeni Chimbe,Norbert Heinrich
The Lancet Infectious Diseases Vol 26(1):p5
5
Diversifying antimalarial treatment for uncomplicated Plasmodium falciparum malaria in Uganda
乌干达针对无并发症恶性疟原虫疟疾的抗疟治疗多样化
Arjen M Dondorp
The Lancet Infectious Diseases Vol 26(1):p6
6
A safe start for PfSPZ Vaccine, but efficacy in children remains elusive
PfSPZ疫苗安全起步，但在儿童中的疗效仍难以捉摸
Nicholas Aderinto,Temitomi Jane Oyedele
The Lancet Infectious Diseases Vol 26(1):p8
7
Rifasutenizol-based triple therapy for Helicobacter pylori infection
以利法苏替尼唑为基础的三联疗法治疗幽门螺杆菌感染
Jinnan Chen,Hong Lu
The Lancet Infectious Diseases Vol 26(1):p9
8
The smallest faith
最渺小的信念
Steven A Pergam
The Lancet Infectious Diseases Vol 26(1):p11
9
Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease
新冠肺炎长期症状临床试验的阴性结果：为异质性疾病选择预后指标
Lara Goxhaj,Lisa McCorkell,Femke van Rhijn-Brouwer,Letícia Soares,Julia Moore Vogel,Chloé de Canson
The Lancet Infectious Diseases Vol 26(1):p13
10
Strengthening global preparedness and response to arboviral disease threats: a call to action
加强全球应对虫媒病毒疾病威胁的准备和响应：行动呼吁
WHO Global Arbovirus Initiative Technical Advisory Group
世界卫生组织全球虫媒病毒倡议技术咨询小组
The Lancet Infectious Diseases Vol 26(1):p15
11
Introducing our cover artist for 2026: Daria Lada
介绍我们2026年的封面艺术家：达里亚·拉达
Marco De Ambrogi
The Lancet Infectious Diseases Vol 26(1):p17
Correspondence（读者来信）
12
Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2
新兴新冠病毒变异株BA.3.2的流行病学和病毒学最新情况
Lu Zhang,Nianzhen Chen,Amy Eichmann,Inga Nehlmeier,Anna-Sophie Moldenhauer,Metodi V Stankov,Christine Happle,Alexandra Dopfer-Jablonka,Georg M N Behrens,Markus Hoffmann,Stefan Pöhlmann
The Lancet Infectious Diseases Vol 26(1):e1
13
Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation
Christine Happle,Markus Hoffmann,Metodi V Stankov,Inga Nehlmeier,Amy Eichmann,Torsten LP.8.1适应性mRNA疫苗接种对新冠病毒变异株中和作用的影响
Witte,Luis Manthey,Stefan Pöhlmann,Alexandra Dopfer-Jablonka,Georg M N Behrens
The Lancet Infectious Diseases Vol 26(1):e3
14
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致
Nader Ebrahimi,Amir Ghaemi
The Lancet Infectious Diseases Vol 26(1):e6
15
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance – Authors' reply
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致——作者回复
Frank Aarestrup,Marion Koopmans
The Lancet Infectious Diseases Vol 26(1):e7
16
Time to tackle vaccine–HLA associations with artificial intelligence
是时候用人工智能解决疫苗-人类白细胞抗原关联问题了
Alexander J Mentzer,George Davey Smith,Teresa Lambe,Julian C Knight,Mary Carrington
The Lancet Infectious Diseases Vol 26(1):e8
Corrections（更正）
17
Correction to Lancet Infect Dis 2025; published online Oct 29.
《柳叶刀-传染病》2025年更正；在线发表于10月29日
https://doi.org/10.1016/S1473-3099(25)00466-9
The Lancet Infectious Diseases Vol 26(1):e9
18
Correction to Lancet Infect Dis 2025; published online Oct 27.
《柳叶刀-传染病》2025年更正；在线发表于10月27日
https://doi.org/10.1016/S1473-3099(25)00546-8
The Lancet Infectious Diseases Vol 26(1):e9
19
Correction to Lancet Infect Dis 2025; 25: 1084–96
《柳叶刀-传染病》2025年更正；25卷：1084-1096页
The Lancet Infectious Diseases Vol 26(1):e9
20
Correction to Lancet Infect Dis 2025; published online Nov 10.
《柳叶刀-传染病》2025年更正；在线发表于11月10日
https://doi.org/10.1016/S1473-3099(25)00550-X
The Lancet Infectious Diseases Vol 26(1):e9
Newsdesk（新闻台）
21
Highlights of IDWeek 2025
2025年IDWeek亮点
Phoebe Hall
The Lancet Infectious Diseases Vol 26(1):e10
22
WHO publishes update on global antibiotic resistance
世界卫生组织发布全球抗生素耐药性最新情况
Timothy Jesudason
The Lancet Infectious Diseases Vol 26(1):e11
23
European Commission to fund new medicines for dengue
欧盟委员会资助登革热新药研发
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):e12
24
Second report from the UK Covid-19 Inquiry
英国新冠肺炎调查第二次报告
Talha Burki
The Lancet Infectious Diseases Vol 26(1):e13
25
Infectious disease surveillance update
传染病监测最新情况
Cahal McQuillan
The Lancet Infectious Diseases Vol 26(1):e14
26
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases Vol 26(1):e15
Obituary（讣告）
27
Jean Louis Abdourahim Ndiaye
让·路易斯·阿卜杜拉希姆·恩迪亚耶
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):p19
Profile（人物介绍）
28
Fortunate Machingura—tackling climate change and disease
福图纳特·马辛古拉——应对气候变化与疾病
Tony Kirby
The Lancet Infectious Diseases Vol 26(1):p20
Media Watch（媒体观察）
Book（书籍）
29
The social and political drivers behind pandemics
大流行背后的社会和政治驱动因素
Emma Louise Fabiani
The Lancet Infectious Diseases Vol 26(1):p21
Articles（论著）
30
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study
新冠肺炎疫情后美国儿童地方性病毒重新出现的动态（2022-23年）：一项前瞻性、多中心、纵向、免疫流行病学监测研究
Hai Nguyen-Tran,Sang Woo Park,Matthew R Vogt,Perdita Permaul,Alicen B Spaulding,Michelle L Hernandez,Jennifer A Bohl,Sucheta Godbole,Tracy J Ruckwardt,Peter W Krug,Daniel L Moss,Alexandrine Derrien-Colemyn,Ananda Chowdhury,Gabrielle Dziubla,Lu Wang,Mike Castro,Sandeep R Narpala,Elizabeth R Longtine,Amy R Henry,Teri-T B Ngo,Leonid Dzantiev,George B Sigal,C Jessica Metcalf,David W Kimberlin,Samuel R Dominguez,Abraham Mittelman,Adrian B McDermott,Leonid A Serebryannyy,Bryan Grenfell,Kevin Messacar,Daniel C Douek
The Lancet Infectious Diseases Vol 26(1):p22
31
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
索托维单抗与常规治疗对住院新冠肺炎患者的疗效对比（RECOVERY）：一项随机、对照、开放标签、平台试验
RECOVERY Collaborative Group
RECOVERY协作组
The Lancet Infectious Diseases Vol 26(1):p34
32
A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial
含氯法齐明-利福喷丁的3个月方案与标准治疗方案治疗药物敏感性结核病的对比（Clo-Fast）：一项随机、开放标签、2c期临床试验
John Z Metcalfe,Isabelle R Weir,Kimberly K Scarsi,Alberto Mendoza-Ticona,Samuel Pierre,Luke Hall,Jorge Leon-Cruz,Elin M Svensson,Simon E Koele,Wadzanai Samaneka,Cecilia Kanyama,Maxwell Yohane,Neetal Nevrekar,Busisiwe Ntsalaze,Jean Bernard Marc,Melanie Goth,Gary Maartens,Richard Chaissonon behalf of the ACTG A5362 study team
The Lancet Infectious Diseases Vol 26(1):p46
33
Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories
2021-22年全球应对抗菌药物耐药性的政策反应：对161个国家和地区进行的系统性治理分析
Jay Patel,Sahar Saeedi Moghaddam,Sruthi Ranganathan,Neil Vezeau,Emily O'Neill,Anne Harant,Michael Stolpe,Lothar H Wieler,Tim Eckmanns,Devi Sridhar
The Lancet Infectious Diseases Vol 26(1):p55
34
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial
乌干达6个月至10岁儿童使用蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-吡喃隆治疗无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签、4期临床试验
Moses R Kamya,Joaniter I Nankabirwa,Chris Ebong,Victor Asua,Moses Kiggundu,Stephen Orena,Martin Okitwi,Stephen Tukwasibwe,Bosco Agaba,Daniel Kyabayinze,Jimmy Opigo,Damian Rutazana,Benjamin Binagwa,Edward Mugwanya,Shakira Babirye,Gloria Sebikaari,Patrick M Condo,Grace Appiah,Sam L Nsobya,Melissa D Conrad,Philip J Rosenthal,Leah F Moriarty,Adoke Yeka
The Lancet Infectious Diseases Vol 26(1):p67
35
Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial
加蓬儿童使用辐射减毒全孢子虫疟疾疫苗的安全性、耐受性和保护效力：一项随机、双盲、安慰剂对照、2期试验
Selidji T Agnandji,Jeroen Bok,Ayodele Alabi,Anita L Kabwende,Armel Mbouna,Juste Bie,Eleonne Moukiti,Albert Lalremruata,Meral Esen,Andrea Kreidenweiss,Natasha KC,B Kim Lee Sim,Thomas L Richie,L W Preston Church,Matthew B B McCall,Stephen L Hoffman,Peter G Kremsner,Benjamin Mordmüller
The Lancet Infectious Diseases Vol 26(1):p79
36
Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study
TAK-003登革热疫苗在2024年圣保罗暴发期间对青少年的有效性：一项测试阴性病例对照研究
Otavio T Ranzani,Felippe Lazar Neto,Lisany Krug Mareto,Thiago Sanches Brumatti,Roberto Dias de Oliveira,Patricia Vieira da Silva,Edinéia Ribeiro dos Santos,Tatiana Lang D' Agostini,Regiane A Cardoso De Paula,Natalie E Dean,Albert I Ko,Derek A T Cummings,Jason R Andrews,Matt D T Hitchings,Julio Croda
The Lancet Infectious Diseases Vol 26(1):p91
37
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial
以利法苏替尼唑为基础的三联疗法与铋剂加克拉霉素为基础的三联疗法作为中国幽门螺杆菌感染一线治疗的对比（EVEREST-HP）：一项3期、多中心、随机、三模拟、双盲、对照、非劣效性试验
Zhiqiang Song,Liya Zhou,Weihong Wang,Cheng Lan,Tongyu Tang,Jun Xie,Huizhen Fan,Xuehong Wang,Xiuli Zuo,Yin Zhu,Chengxia Liu,Yongsong Gu,Huang Feng,Xiang Gao,Qing Zhang,Hong Zhang,Jing Chen,Guozhu Geng,Zhenkun Maon behalf of the EVEREST-HP Study Group
The Lancet Infectious Diseases Vol 26(1):p101
Series（专题研讨会）
38
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Innovation in active and passive immunisation of people who are immunocompromised: a call to action
免疫功能低下人群主动和被动免疫接种的创新：行动呼吁
Joshua A Hill,Jim Boonyaratanakornkit,Malgorzata Mikulska,Benjamin W Teh,William O Hahn,Ghady Haidar,Catherine Liu,Deepali Kumar,Michael G Ison,Natasha Halasa
The Lancet Infectious Diseases Vol 26(1):e16
39
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship
应对免疫功能低下人群的抗菌药物耐药性：利用诊断和抗菌药物管理
Catherine Liu,Emily A Rosen,Erica J Stohs,Hannah Imlay,Masayuki Nigo,Lee S Gottesdiener,Miranda So,Frank Tverdek,Sanjeet Dadwal,Carlota Gudiol,Michael J Satlin,Susan K Seo,Jason A Trubiano,Ritu Banerjee,Kimberly E Hanson,Lilian M Abbo
The Lancet Infectious Diseases Vol 26(1):e30
Review（综述）
40
Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project
揭示欧洲肺泡棘球蚴病的发病率和趋势：来自KNOW-PATH项目的系统综述
Adriano Casulli,Bernadette Abela,Daniele Petrone,Barbara Šoba,Balázs Dezsényi,Jacek Karamon,Laurence Millon,Urmas Saarma,Daniela Antolová,François Chappuis,Severin Gloor,Marcel Stoeckle,Beat Müllhaupt,Relja Beck,Heimo Lagler,Felix Lötsch,Herbert Auer,Marie-Pierre Hayette,Libuše Kolářová,Sniedze Laivacuma,Mindaugas Šarkūnas,Vitalijus Sokolovas,Audronė Marcinkutė,Karin Troell,Ansgar Deibel,Pikka Jokelainen,Małgorzata Sulima,Dagny Krankowska,Stillhard Roman,Gaëtan-Romain Joliat,Nermin Halkic,Solange Bresson-Hadni,Joanna Halina Bednarek,Andrzej Załęski,Małgorzata Paul,Sheraz Yaqub,Mogens Jensenius,Joke van der Giessen,Laura Nabarro,Peter Chiodini,Florent Demonmerot,Jenny Knapp,Beate Grüner,Peter Kern,Lynn Peters,Federica Santolamazza,Azzurra Santoro
The Lancet Infectious Diseases Vol 26(1):e49
Personal View（个人观点）
41
Azithromycin mass drug administration: balancing survival benefits and risks in children
阿奇霉素大规模药物给药：平衡儿童生存益处与风险
Nubwa Medugu,Ian C Michelow,Claudette Poole,Stephen K Obaro
The Lancet Infectious Diseases Vol 26(1):e62
Clinical Picture（临床影像）
42
Unexpected finding in a 17-year-old female undergoing screening colonoscopy
17岁女性接受筛查结肠镜检查时的意外发现
Ziheng Calvin Xu,Ethan Tan,Mayur Garg
The Lancet Infectious Diseases Vol 26(1):e75
THE LANCET Infectious Diseases. Volume 26Number 2
柳叶刀传染病学 26卷 2期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
Call for letters
征稿启事
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p111
Comment（述评）
2
Long COVID is here to stay—even in children
长期新冠症状将持续存在——即使在儿童中亦是如此
Danilo Buonsenso
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p112
3
Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment
利托那韦强化版奈玛特韦之外的选择：恩赛特韦在新冠肺炎治疗中的应用
Ming Hong Choi,Ivan Fan Ngai Hung
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p113
4
A new monoclonal in the arMAMentarium against malaria
抗疟“武器库”中的新型单克隆抗体
Freia-Raphaella Lorenz,Matthew B B McCall
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p115
5
Household transmission of mpox in Africa: limited in adults but more prevalent in children
非洲猴痘家庭传播情况：在成人中传播有限，但在儿童中更为普遍
Oriol Mitjà,Michael Marks
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p117
6
The lasting lessons of mpox: infection, vaccination, and immune memory
猴痘带来的持久教训：感染、疫苗接种和免疫记忆
Raianna Fantin,Camila H Coelho
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p118
7
Xpert-Ultra for diagnosing asymptomatic tuberculosis
Xpert-Ultra用于诊断无症状结核病
Xia Yu,Hairong Huang
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p120
8
The genomic surveillance gap: averting the antimicrobial resistance pandemic requires global equity and action
基因组监测的差距：避免抗菌药物耐药性大流行需要全球公平与行动
David M Aanensen,Iruka N Okeke,Pilar Donado-Godoy,Beverly Egyir,Ravikumar K Lingegowda,Sonia Siaon behalf of the NIHR Global Health Research Unit on Genomic Surveillance of AMR
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p122
Correspondence（读者来信）
9
Spillover in dengue trials
登革热试验中的溢出效应
Thomas A Smith,Samuel I Watson
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e77
10
Spillover in dengue trials – Author's reply
登革热试验中的溢出效应——作者回复
Fernando Abad-Franch
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e78
11
Updating the traditional voriconazole trough concentration range
传统的伏立康唑谷浓度范围更新
Rongqiang Liao,Xiaoyuan Zheng
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e79
12
Updating the traditional voriconazole trough concentration range – Authors' reply
传统的伏立康唑谷浓度范围更新——作者回复
Inderpaul Singh Sehgal,Ritesh Agarwal,Valliappan Muthu
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e80
13
Clinical course and neurological profile of Kyasanur Forest disease
基萨努尔森林病的临床病程和神经特征
Nitin Gupta,Tirlangi Praveen Kumar
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e82
Corrections（更正）
14
Correction to Lancet Infect Dis 2025; published online Oct 10. https://doi.org/10.1016/S1473-3099(25)00482-7
对《柳叶刀-传染病》2025年发表内容的更正；10月10日在线发表。https://doi.org/10.1016/S1473-3099(25)00482-7
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83
15
Correction to Lancet Infect Dis 2025; published online Dec 1. https://doi.org/10.1016/S1473-3099(25)00681-4
对《柳叶刀-传染病》2025年发表内容的更正；12月1日在线发表。https://doi.org/10.1016/S1473-3099(25)00681-4
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83
Newsdesk（新闻台）
16
Promising early data for sorfequiline
索氟维林早期数据令人鼓舞
Ed Holt
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e84
17
Highlights from ASTMH 2025
2025年美国热带医学与卫生学会年会亮点
Marco De Ambrogi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e85
18
Brazil approves domestic single-shot dengue vaccine
巴西批准国产单剂登革热疫苗
Marcia Triunfol
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e86
19
CDC cuts to childhood vaccine recommendations
美国疾控中心削减儿童疫苗接种建议
Priya Venkatesan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e87
20
WHO launches unified plan for coronaviruses
世界卫生组织启动冠状病毒统一计划
Talha Burki
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e88
21
Infectious disease surveillance update
传染病监测更新
Cahal McQuillan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e89
22
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e90
Obituary（讣告）
23
Walter Dowdle
沃尔特·道德尔
Sanjeet Bagcchi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p124
Profile（人物简介）
24
Katie Anders—improving global dengue control
凯蒂·安德斯——改善全球登革热防控
Tony Kirby
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p125
Media Watch（媒体观察）
Film（电影）
25
Eliminating Guinea worm
根除麦地那龙线虫
Sanjeet Bagcchi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p126
Articles（论著）
26
Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study
奥密克戎时代儿童与青少年长期新冠症状与SARS-CoV-2再感染的关联（RECOVER-EHR）：一项回顾性队列研究
Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Ting Zhou,Michael J Becich,Yuriy Bisyuk,Frank Blanceró,Elizabeth A Chrischilles,Cynthia H Chuang,Lindsay G Cowell,Daniel Fort,Carol R Horowitz,Susan Kim,Nathalia Ladino,David M Liebovitz,Mei Liu,Abu S M Mosa,Hayden T Schwenk,Srinivasan Suresh,Bradley W Taylor,David A Williams,Jeffrey S Morris,Christopher B Forrest,Yong Chenon behalf of the RECOVER Consortium
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p127
27
Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
口服恩赛特韦与口服利托那韦强化版奈玛特韦在新冠肺炎治疗中的抗病毒疗效（PLATCOV）：一项开放标签、2期、随机、对照、适应性试验
William H K Schilling,Podjanee Jittamala,Phrutsamon Wongnak,James A Watson,Simon Boyd,Viravarn Luvira,Tanaya Siripoon,Thundon Ngamprasertchai,Elizabeth M Batty,Ellen Beer,Shivani Singh,Tanatchakorn Asawasriworanan,Timothy Seers,Koukeo Phommasone,Terry John Evans,Varaporn Kruabkontho,Thatsanun Ngernseng,Jaruwan Tubprasert,Mohammad Yazid Abdad,Wanassanan Madmanee,Jindarat Kouhathong,Kanokon Suwannasin,Watcharee Pagornrat,Tianrat Piteekan,Borimas Hanboonkunupakarn,Kittiyod Poovorawan,Manus Potaporn,Attasit Srisubat,Bootsakorn Loharjun,Kesinee Chotivanich,Mallika Imwong,Sasithon Pukrittayakamee,Arjen M Dondorp,Nicholas P J Day,Watcharapong Piyaphanee,Weerapong Phumratanaprapin,Nicholas J Whiteon behalf of the PLATCOV Collaborative Group
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p139
28
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial
头孢地尔与标准疗法治疗医院获得性和医疗保健相关性革兰氏阴性菌血流感染（GAME CHANGER试验）：一项开放标签、平行分组、随机试验
David L Paterson,Helmi Sulaiman,Po-Yu Liu,Mark D Chatfield,Mesut Yilmaz,Zeti Norfidiyati Salmuna,Mohd Zulfakar Mazlan,Siriluck Anunnatsiri,Rujipas Sirijatuphat,Darunee Chotiprasitsakul,David C Lye,Jyoti Somani,Shirin Kalimuddin,Abdullah T Aslan,Visanu Thamlikitkul,Yi-Tzu Lee,Ya-Sung Yang,Yi-Tsung Lin,Wan Nurliyana Wan Ramli,Chien-Hao Tseng,Sophia Archuleta,Yvonne Fu Zi Chan,Brian M Forde,Hugh Wright,Adam G Stewart,Kay A Ramsay,Weiping Ling,Vicki Rossi,Tiffany M Harris-Brown,Patrick N A Harrison behalf of the GAME CHANGER Trial Investigators
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p148
29
Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a 坦桑尼亚学龄前儿童感染毛首鞭形线虫时，递增剂量口服分散片伊维菌素与阿苯达唑联合用药的疗效和安全性：一项单盲、随机、对照、剂量递增、2期试验
single-blind, randomised, controlled, dose-ranging, phase 2 trial
Viviane P Sprecher,Annina Schnoz,Stefan Biendl,Halima S Hussein,Sarah O Najim,Mohammed N Ali,Ibrahim S Mohammed,Said M Ali,Jan Hattendorf,Jennifer Keiser
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p160
30
Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial
人源单克隆抗体MAM01保护美国成年人免受疟疾侵害：一项首次人体、1期、剂量递增、双盲、安慰剂对照、适应性试验
Kirsten E Lyke,Andrea A Berry,Matthew B Laurens,Jennifer Winkler,Sudhaunshu Joshi,Abra Rachida Koudjra,Lauryn Butler,Peter F Billingsley,Tales Pascini,Asha Patil,B Kim Lee Sim,Grace Fitzgerald,Julie Riegel,Kayla Andrews,Micha Levi,Aparna B Anderson,Charles D Wells,Hong Liu,James Huleatt,R Scott Miller
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p170
31
Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study
布隆迪Ib分支猴痘家庭传播动力学特征：一项前瞻性队列研究
Raoul Kamadjeu,Ferdinand Nsengimana,Manassé Nimpagaritse,Edna Moturi,Eric Kezakarayagwa,Rose Nkiko,Jonas Ngendakumana,Rémy Nimubona,Liliane Nkengurutse,Hamady Ba,Dionis Nizigiyimana,Paul Ngwakum,Mame Selbee Diouf,France Bégin,Joseph Nyandwi,Douglas James Noble
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p182
32
Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study
比利时猴痘病毒感染或改良痘苗病毒安卡拉株疫苗接种的长期后果（MPX-COHORT和POQS-FU-PLUS）：一项为期24个月的前瞻性和回顾性队列研究
Christophe Van Dijck,Nicole Berens-Riha,Luca M Zaeck,Cécile Kremer,Jacob Verschueren,Jasmine Coppens,Fien Vanroye,Elisabeth Willems,Evi Bosman,Natalie De Cock,Bart Smekens,Leen Vandenhove,Odin Goovaerts,Anke Van Hul,Janne Wouters,Bart K M Jacobs,Stefanie Bracke,Matilde Hens,Isabel Brosius,Elise De Vos,Eugene Bangwen,Sarah Houben,Achilleas Tsoumanis,Pedro Henrique Lopes Ferreira Dantas,Jojanneke Rutgers,Amber Lipman,Koen Wijnans,Patrick Soentjens,Emmanuel Bottieau,Chris Kenyon,Johan van Griensven,Thijs Reyniers,Niels Horst,Kevin K Ariën,Marjan Van Esbroeck,Andrea Torneri,Koen Vercauteren,Wim Adriaensen,Rory D de Vries,Joachim Mariën,Laurens Liesenborghs
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p190
33
Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study
乌干达Xpert Ultra微量筛查结果阳性个体患结核病的长期风险：一项纵向随访研究
Joowhan Sung,Mariam Nantale,Annet Nalutaaya,Patrick Biché,James Mukiibi,Joab Akampurira,Rogers Kiyonga,Francis Kayondo,Michael Mukiibi,Caitlin Visek,Caleb E Kamoga,David W Dowdy,Achilles Katamba,Emily A Kendall
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p203
Review（综述）
34
Invasive group A streptococcal infections: lessons learned from the 2022–23 upsurge
侵袭性A组链球菌感染：从2022-23年激增中吸取的教训
Alix Flamant,Alicia Demirjian,Theresa Lamagni,Julie Toubiana,Pierre R Smeesters,Jérémie F Cohen
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e91
35
A clinical practice guideline for tuberculous meningitis
结核性脑膜炎临床实践指南
Joseph Donovan,Fiona V Cresswell,Elizabeth W Tucker,Angharad G Davis,Ursula K Rohlwink,Julie Huynh,Regan Solomons,James A Seddon,Nathan C Bahr,Arjan van Laarhoven,Suzanne T Anderson,Sanjay K Jain,Felicia C Chow,Sophie Pattison,James E Scriven,Gabriela Singh,Rob E Aarnoutse,Jan-Willem C Alffenaar,Sofiati Dian,Abi Manesh,Robin Basu Roy,Varinder Singh,Ronald van Toorn,Caryn M Upton,Reinout van Crevel,Kelly E Dooley,Diana Gibb,David Meya,Robert J Wilkinson,Ewelina Rogozińska,Usha K Misra,Anthony Figaji,Guy E Thwaites
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e96
36
Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults
缩短念珠菌血症疗程：界定成人非复杂性念珠菌血症
Ilana Reinhold,Susanne Picardi,Blasius Liss,Danila Seidel,Jannik Stemler,Philipp Koehler,Tamara Ruegamer,Rosanne Sprute,Oliver A Cornely
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e112
Personal View（个人观点）
37
A transformation in cholera surveillance
霍乱监测的变革
Amanda K Debes,Erin T Baumgartner,Kendra N Williams,David A Sack
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e124
Clinical Picture（临床图像）
38
Paediatric ocular toxocariasis with relentless progression despite negative metagenomic testing
尽管宏基因组检测呈阴性，但儿科眼弓蛔虫病仍持续进展
Diya Shah,Shiama Balendra,Harry Petrushkin,Anamika Patel
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e130
THE LANCET Infectious Diseases. Volume 26Number 3
柳叶刀传染病学 26卷 3期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL（社论）
1
Promises and challenges of AI in infectious diseases
人工智能在传染病领域的承诺与挑战
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p213
COMMENT（述评）
2
More real-world evidence for RSV vaccines in the global community
全球范围社区呼吸道合胞病毒（RSV）疫苗的更广泛的现实证据
Kristina L Bajema,Wesley H Self
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p214
3
Rapid diagnostic antigen tests for mpox and the need for decentralised testing—not quite there yet
猴痘快速诊断抗原检测及分散检测的必要性——尚待完善
Daniel Mukadi-Bamuleka,Kevin K Ariën
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p215
4
Solving the data bottleneck for artificial intelligence in infectious diseases
解决传染病人工智能领域的数据瓶颈问题
Cesar de la Fuente-Nunez
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p217
5
Artificial intelligence and One Health: potential for spillover prediction?
人工智能与“同一健康”理念：能否预测病原体外溢？
Marion Koopmans,Istvan Csabai,Daniel Remondini,Emma Snary,Frank Aarestrup
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p219
6
Artificial intelligence in the development of vaccines for infectious diseases
人工智能在传染病疫苗研发中的应用
Steve Black,Shabir A Madhi,Rino Rappuoli
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p221
7
Peer review at The Lancet Infectious Diseases in 2025
2025年《柳叶刀-传染病学》期刊专家评审
Ursula Hofer
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p223
8
Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2025
感谢2025年《柳叶刀-传染病学》期刊的统计学及评审专家
The Lancet Infectious Diseases Editors
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e132
CORRESPONDENCE（读者来信）
9
Methodological considerations in the attribution of long COVID to first or second infection
首次或二次感染导致长期新冠症状的方法学考量
Sara Carazo,Danuta M Skowronski,Manale Ouakki,Gaston De Serres
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e139
10
Methodological considerations in the attribution of long COVID to first or second infection – Authors' reply
首次或二次感染导致长期新冠症状的方法学考量——作者回复
Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Christopher B Forrest,Yong Chen
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e141
11
Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2
LP.8.1单价疫苗针对包括XEC、LP.8.1、NB.1.8.1、XFG和BA.3.2在内的多种SARS-CoV-2变异株的体液免疫应答
Yu Kaku,Mizuka Fujiwara,Keiya Uriu,Maximilian Stanley Yo,Shusuke Kawakubo,Jumpei Ito,Naoya Itoh,Yoshifumi Uwamino,Fumitake Saito,Hironori Satoh,The Genotype to Phenotype Japan (G2P-Japan) Consortium,Kei Sato
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e142
12
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance
金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者
Brenda A Warecki,María F Mojica,Alejandro J Vila,Robert A Bonomo
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e144
13
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply
金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者——作者回复
David L Paterson,Abdullah T Aslan,Patrick N A Harris
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e145
CORRECTIONS（更正）
14
Correction to Lancet Infect Dis 2025; published online Dec 9. https://doi.org/10.1016/S1473-3099(25)00659-0
《柳叶刀-传染病学》2025年发表文章勘误；在线发表于12月9日。https://doi.org/10.1016/S1473-3099(25)00659-0
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146
15
Correction to Lancet Infectious Diseases 2026; published online Jan 20. https://doi.org/10.1016/S1473-3099(25)00773-X
《柳叶刀-传染病学》2026年发表文章勘误；在线发表于1月20日。https://doi.org/10.1016/S1473-3099(25)00773-X
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146
NEWSDESK（新闻台）
16
Rabies an increasing threat in Ukraine
乌克兰狂犬病威胁日益加剧
Ed Holt
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e147
17
People needing trachoma interventions at record low
需要沙眼干预措施的人数创历史新低
Timothy Jesudason
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e148
18
Uneven STI response in EU/EEA countries
欧盟/欧洲经济区国家性传播感染应对措施不均衡
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e149
19
Controversial HBV vaccine trial in Guinea-Bissau halted
几内亚比绍有争议的乙型肝炎病毒疫苗试验被叫停
Talha Burki
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e150
20
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e151
OBITUARY（讣告）
21
Ivan Hirsch
伊万·赫希
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p224
PROFILE（人物介绍）
22
Reem Abu Shomar— championing water safety in Gaza
里姆·阿布·舒马尔——加沙地带水安全倡导者
Tony Kirby
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p225
MEDIA WATCH（媒体观察）
Book（书籍）
23
A prescription for public health literacy
提升公众健康素养的良方
Vijay Shankar Balakrishnan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p226
Book（书籍）
24
Imagining the inevitable
想象不可避免之事
Cahal McQuillan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p227
Film（电影）
25
Women's autonomy, safe sex and HIV prevention
女性自主权、安全性行为与艾滋病预防
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p228
ARTICLES（论著）
26
Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study
英国75-79岁成年人中双价呼吸道合胞病毒（RSV）预融合F蛋白疫苗对RSV相关住院的有效性：一项多中心、检测阴性、病例对照研究
Rebecca Symes,Heather J Whitaker,Shazaad Ahmad,David Arnold,Suryabrata Banerjee,Cariad M Evans,Robin Gore,Jennifer Hart,Katy Heaney,Onn Min Kon,Anne Melhuish,Munira Ortale Zogaib,Emanuela Pelosi,Najib M Rahman,Gerrit Woltmann,Tricia McKeever,Maria Zambon,Conall H Watson,Wei Shen Lim,Jamie Lopez Bernalon behalf of the HARISS network collaborators
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p229
27
Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial
印度治疗初治慢性肺曲霉病患者口服伊曲康唑与口服伏立康唑的对比研究（VICTOR-CPA试验）：一项单中心、开放标签、随机、对照、优效性试验
Inderpaul Singh Sehgal,Ritesh Agarwal,Sahajal Dhooria,Kuruswamy Thurai Prasad,Valliappan Muthu,Ashutosh Nath Aggarwal,Shivaprakash M Rudramurthy,Mandeep Garg,Arunaloke Chakrabarti
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p239
28
Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial
血流感染抗生素治疗疗程依从性考量（BALANCE）：一项随机临床试验的事后分析
Sean W X Ong,Ruxandra Pinto,Robert K Mahar,Asgar Rishu,Joshua S Davis,Robert A Fowler,Steven Y C Tong,Nick Danemanfor the BALANCE trial consortium
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p250
29
Field evaluation of a rapid antigen test for mpox in the Democratic Republic of the Congo and Uganda: a multicentre, prospective, diagnostic accuracy study
刚果民主共和国和乌干达猴痘快速抗原检测的现场评估：一项多中心、前瞻性、诊断准确性研究
Barnabas Bakamutumaho,David Lupande Mwenebitu,Winters Muttamba,Ingrid Ampeire,Henry Kyobe Bosa,Esto Bahizire,Bertin Casinga Bisimwa,Andrew Obuku,Misaki Wayengera,Alison Sandeman,Matthew T G Holden,Patrick D M C Katoto,Bruce Kirenga,Deborah A Williamson,Wilber Sabiiti
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p260
30
Complications and mortality of typhoid fever: an updated global systematic review and meta-analysis
伤寒热的并发症与死亡率：一项更新的全球系统综述与荟萃分析
Shruti Murthy,Nienke N Hagedoorn,Suzanne Faigan,Meera D Rathan,Christian S Marchello,John A Crump
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p270
31
Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
1990-2023年全球、区域和国家层面查加斯病负担：2023年全球疾病负担研究的系统分析
GBD 2023 Chagas Disease and RAISE Study Collaborators
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p284
32
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
乌干达健康成年人中ChAdOx1裂谷热疫苗的安全性、耐受性和免疫原性：一项单中心、单盲、随机、安慰剂对照、剂量递增的1期试验
Zacchaeus Anywaine,Jennifer Serwanga,Abu-Baker Mustapher Ggayi,Andrew Max Abaasa,Daniel Wright,Ben Gombe,Peter Ejou,Tamara Namata,Antony Kigozi,Naboth Tukamwesiga,Vincent Basajja,Violet Ankunda,Dora Jocelyn Mulondo,Florence Nambaziira,Ayoub Kakande,Wilson Kakeeto,Phiona Nabaggala,Daniel Jenkin,Alison Lawrie,Pedro Folegatti,Nguyen Tran,Christian Hansen,Alison M Elliott,Adrian V S Hill,George M Warimwe,Pontiano Kaleebu
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p302
33
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial
美国儿童、青少年和成人基础免疫后18个月VLA15莱姆病疫苗候选物的加强免疫接种的免疫原性和安全性：一项随机、观察者盲法、安慰剂对照的2期试验
Laura Wagner,Michaela Obersriebnig,Romana Hochreiter,Vera Kadlecek,Julian Larcher-Senn,Lisa Hegele,Jason D Maguire,Timothy Murphy,Ulla Derhaschnig,Nicole Bézay,Juan Carlos Jaramillo,Susanne Eder-Lingelbach,Marc Messier
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p314
SERIES（研讨会）
Artificial Intelligence and Infectious Diseases
人工智能与传染病
34
Artificial intelligence and infectious diseases: an evidence-driven conceptual framework for research, public health, and clinical practice
人工智能与传染病：基于证据的研究、公共卫生和临床实践概念框架
Anna Odone,Chiara Barbati,Silvia Amadasi,Tanja Schultz,David B Resnik
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e152
35
Artificial intelligence and infectious disease diagnostics: state of the art and future perspectives
人工智能与传染病诊断：现状与未来展望
Luca Miglietta,Timothy M Rawson,Ronald Galiwango,Alex Tasker,Damien K Ming,Darlington Akogo,Cecilia Ferreyra,Eric O Aboagye,N Claire Gordon,Carolina Garcia-Vidal,Jesus Rodriguez-Manzano,Alison H Holmes
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e168
36
Artificial intelligence and infectious diseases: tackling antimicrobial resistance, from personalised care to antibiotic discovery
人工智能与传染病：应对抗菌药物耐药性，从个性化治疗到抗生素发现
Alex Howard,Nada Reza,Peter L Green,Mo Yin,Erin Duffy,Henry C Mwandumba,Alessandro Gerada,William Hope
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e181
REVIEW（综述）
37
Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia
血液系统恶性肿瘤患者或接受造血细胞移植患者社区获得性呼吸道病毒感染：第10届欧洲白血病感染会议更新建议
Marie von Lilienfeld-Toal,Fareed Khawaja,Francesca Compagno,Christine Robin,José-Luis Piñana,Simone Cesaro,Hermann Einsele,Per Ljungman,David Navarro,Michael Boeckh,Roy F Chemaly,Hans H Hirsch
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e193
CLINICAL PICTURE（临床图像）
38
Mycoplasma hominis toe osteomyelitis: a rare and unusual bone infection
人型支原体足趾骨髓炎：一种罕见且不寻常的骨感染
Cheryl Keel,Pauleen McSherry,Rebecca Thombre,Sendurann Nadarajah,Rediat Tewolde,Owen B
Spiller,Baharak Afshar
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e207
THE LANCET Infectious Diseases. Volume 26Number 4
柳叶刀传染病学 26卷 4期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
GoGoVax dispels hopes for gonorrhoea vaccination
GoGoVax让淋病疫苗的希望破灭
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p329
COMMENT（述评）
2
Do the benefits of universal screening outweigh the harms?
全民筛查的益处是否大于害处？
Alanna N Gillespie,Emma Webb,Valerie Sung
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p330
3
Chikungunya in Brazil: vaccination strategies informed by mathematical modelling
巴西基孔肯雅热：基于数学建模的疫苗接种策略
José Lourenço,Marta Giovanetti
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p331
4
Chikungunya adolescent vaccination and the distinct risk–benefit landscapes
青少年接种基孔肯雅热疫苗及独特的风险-获益情况
Ernesto T A Marques,Simon Barratt-Boyes
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p333
5
Circulation of clade Ib mpox outside of Africa—are we prepared?
非洲以外地区Ib分支猴痘的传播——我们准备好了吗？
Seth D Judson,Claude Kwe Yinda,Franziska K Kaiser,Daniel S Chertow,Emmie de Wit,James O Lloyd-Smith,Vincent J Munster
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p334
6
I worked at WHO: the USA leaving will not make America healthier
我曾在世卫组织工作：美国退出不会让美国更健康
Krutika Kuppalli
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p336
CORRESPONDENCE（读者来信）
7
Maternal views on RSV vaccination in the UK's second season
英国第二季呼吸道合胞病毒疫苗接种的产妇观点
Shaun O'Hagan,Steve Cunningham,Simon B Drysdale,Helen E Groves,Samantha Hunt,Dalia Iskander,Xinxue Liu,Mark D Lyttle,Chengetai D Mpamhanga,Thomas Waterfield,Thomas C Williams,Robin Marlow,Damian Rolandon behalf of the PERUKI & BronchStart/Stop Collaboration
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e209
8
Overcoming immune imprinting with the COVID-19 LP.8.1 mRNA boosters
利用COVID-19 LP.8.1 mRNA加强针克服免疫印记
Ninaad Lasrado,Annika Rössler,Katherine Molloy,Isabella McConnell,Ritobhas Bhowmik,Francisco Armando Granados-Contreras,Jessica Wu,Alejandra Waller-Pulido,Samuel J Nangle,Erica Borducchi,Ai-ris Y Collier,Dan H Barouch
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e212
CORRECTIONS（更正）
9
Correction to Lancet Infect Dis 2025; published online Nov 27.
https://doi.org/10.1016/S1473-3099(25)00605-X
《柳叶刀-传染病学》2025年刊载内容更正；在线发布于11月27日
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
10
Correction to Lancet Infect Dis 2026; 26: 343–61
《柳叶刀-传染病学》2026年刊载内容更正；26卷：343-61页
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
11
Correction to Lancet Infect Dis 2026; published online Jan 23. https://doi.org/10.1016/S1473-3099(25)00730-3
《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月23日
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
12
Correction to Lancet Infect Dis 2026; published online Jan 28. https://doi.org/10.1016/S1473-3099(25)00747-9
《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月28日
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
NEWSDESK（新闻台）
13
UK loses measles elimination status as cases rise
随着病例增加，英国失去麻疹消除地位
Priya Venkatesan
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e215
14
Brazil launches implementation study of lenacapavir
巴西启动来那卡帕韦实施研究
Tony Kirby
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e216
15
Clade Ib mpox in southwest Indian Ocean islands
西南印度洋岛屿出现Ib分支猴痘
Esther Nakkazi
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e217
16
EMA approves combined COVID-19 and flu mRNA vaccine
欧洲药品管理局批准COVID-19和流感联合mRNA疫苗
Talha Burki
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e218
17
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e219
OBITUARY（讣告）
18
Nicholas John White
尼古拉斯·约翰·怀特
Sanjeet Bagcchi
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p339
PROFILE（人物简介）
19
Katharina Kranzer—led by curiosity, committed to capacity
卡塔琳娜·克兰泽——受好奇心驱使，致力于提升能力
Tony Kirby
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p340
MEDIA WATCH（媒体观察）
Film（电影）
20
Leishmaniasis: a story of two continents
利什曼病：两个大陆的故事
Vijay Shankar Balakrishnan
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p341
Book（书籍）
21
Finding your voice in a world of uncertainty
在不确定的世界中找到自己的声音
Carrie Fielden
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p342
ARTICLES（论著）
22
Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
1990-2023年下呼吸道感染的全球负担及病因：2023年全球疾病负担研究的系统分析
GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators
GBD 2023下呼吸道感染和抗菌素耐药性协作组
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p343
23
Effectiveness of the maternal RSVpreF vaccine against severe disease in infants in Scotland, UK: a national, population-based case–control study and cohort analysis
英国苏格兰地区母体RSVpreF疫苗对婴儿严重疾病的保护效果：一项全国性、基于人群的病例对照研究和队列分析
Isobel McLachlan,Chris Robertson,Kirsty E Morrison,Ross McQueenie,Safraj Shahul Hameed,Cheryl Gibbons,Rachael Wood,Rachel Merrick,Louisa Pollock,Antonia Ho,Ting Shi,Thomas C Williams,Sir Aziz Sheikh,Jim McMenamin,Sam Ghebrehewet,Kimberly Marsh
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p362
24
Post-COVID-19 resurgence of Mycoplasma pneumoniae infections in French children (ORIGAMI): a retrospective and prospective multicentre cohort study
法国儿童COVID-19后支原体肺炎感染的复现（ORIGAMI）：一项回顾性和前瞻性多中心队列研究
Anaïs Chosidow,Zoha Maakaroun-Vermesse,Vichita Ok,Cécile Delecroix,Pascal Le Roux,Marie-Aliette Dommergues,Justine de Larminat,Eric Jeziorski,Pauline Ronjat,Léa Jaume,Anne Welfringer-Morin,Cécile Bébéar,Maud Gits-Muselli,Delphine Viriot,Charles-Joris Roux,Stéphane Bechet,Anne-Sophie Romain,Mathie Lorrot,Robert Cohen,Corinne Levy,Jérémie F Cohenon behalf of the ORIGAMI Study Group
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p374
25
Lessons derived from a 3-year congenital cytomegalovirus screening programme in Israel: a prospective population-based cohort study
以色列先天性巨细胞病毒筛查项目的3年经验教训：一项前瞻性基于人群的队列研究
Smadar Eventov Friedman,Noa Ofek Shlomai,Esther Oiknine-Djian,Tal Sido,Oren Gordon,Sraya Greenberger,Hadar Horowitz,Lior Merav,Stav David Mehaber,Orit Caplan,Miriam Geal-Dor,Natalia Simanovsky,Diana Averbuch,Colin Kunzweiler,Yosefa Hefter,John Diaz-Decaro,Ora Paltiel,Moran Yassour,Dana G Wolf
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p384
26
Comparison of the performance and costs of testing algorithms using rapid diagnostic tests for detection and treatment of syphilis among pregnant individuals and men who have sex with men: a modelling study
使用快速诊断检测方法对孕妇和男男性行为者进行梅毒检测和治疗的不同检测算法的性能和成本比较：一项建模研究
Ying Zhang,Eric P F Chow,Lei Zhang,Christopher K Fairley,Jason J Ong
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p394
27
The epidemiology of chikungunya virus in Brazil and the potential impact of vaccines: a mathematical modelling study
巴西基孔肯雅热病毒的流行病学及疫苗的潜在影响：一项数学建模研究
Oscar Cortes-Azuero,Megan O'Driscoll,Gabriel Ribeiro dos Santos,Ronaldo de Jesus,Shirlene T S de Lima,Danny Scarponi,Christinah Mukandavire,Arminder Deol,Moritz U G Kraemer,William M de Souza,Henrik Salje
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p406
28
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil
青少年接种减毒活基孔肯雅热病毒疫苗的安全性和免疫原性：巴西流行地区一项为期12个月、双盲、随机、安慰剂对照的3期试验最终结果
Vera Buerger,Andrea Pfeiffer,Petra Schoengrundner,Jutta Seebacher,Romana Hochreiter,Karin Kosulin,Oliver Zoihsl,Petronela Weisova,Robert Mader,Ana Paula Loch,Eolo Morandi Jr,Mauricio Lacerda Nogueira,Carlos Alexandre Antunes de Brito,Julio Croda,Mauro Martins Teixeira,Ivo Castelo-Branco Coelho,Ricardo Gurgel,Allex Jardim da Fonseca,Marcus Vinícius Guimarães de Lacerda,Edson Duarte Moreira Jr,Ana Paula Rocha Veiga,Susanne Eder-Lingelbach,Juan Carlos Jaramillo
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p417
29
National burden of and optimal vaccine policy for Japanese encephalitis virus in Bangladesh: a seroprevalence and modelling study
孟加拉国日本脑炎病毒的全国负担及最佳疫苗接种政策：一项血清流行率和建模研究
Mariana Perez Duque,Kishor K Paul,Rebeca Sultana,Gabriel Ribeiro dos Santos,Megan O'Driscoll,Abu M Naser,Mahmudur Rahman,Mohammad Shafiul Alam,Hasan M Al-Amin,Mohammed Z Rahman,Mohammad E Hossain,Repon C Paul,Elias Krainski,Stephen P Luby,Simon Cauchemez,Jessica Vanhomwegen,Emily S Gurley,Henrik Salje
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p429
REVIEW（综述）
30
Autoantibodies in long COVID: a systematic review
长新冠中的自身抗体：一项系统综述
Fabian Wilhelm,Janne Cadamuro,Sylvia Mink
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e220
31
Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE)
登革热临床试验核心结局测量指标集：一项国际德尔菲共识研究（DEN-CORE）
Sophie Yacoub,Anastasia Demidova,Xin Hui S Chan,Ali Ajam,Dina Baimukhambetova,Andreij Horn,Evgeniia Kakotkina,Mark Kosenko,Aigun Mursalova,Jennifer Ilo Van Nuil,Chi Le Phuong,Lin Xiao,Sudeep Adhikari,Juan David Alzate Alvarez,Kathryn B Anderson,Panisadee Avirutnan,Stephanie Buchholz,Richa Chandra,Aileen Y Chang,Ho Quang Chanh,Mónika Patricia Consuegra Rodríguez,Vanessa Daniel,Janet V Diaz,Claudia Figueiredo-Mello,Rosa Margarita Gelvez-Ramírez,Tran Bang Huyen,Evelyne Kestelyn,Phung Khanh Lam,Stije J Leopold,Ruobing Li,Tran Luu,David Chien Boon Lye,Angela McBride,Isabelle Meyer-Andrieux,Nathaniel J Moorman,Nguyet Minh Nguyen,Sharifah Faridah Syed Omar,Hang Cheng Ong,Eng Eong Ooi,Ekaterina Pazukhina,Sarah L Pett,Diego Bastos Porto,Giri S Rajahram,Marc Rogers,Elsa Rojas,James Rosen,Jamie Rylance,William H K Schilling,Andre M Siqueira,Peter Sjö,Alfonso Sucerquia-Hernandez,Dong Thi Hoai Tam,Mauro Martins Teixeira,Andreas Tietz,Huynh Trung Trieu,Annalise Unsworth,Luis Villar,Adam Tully Waickman,James A Watson,Bridget A Wills,Po Ying Chia,Patricia Brasil,Thomas Jaenisch,Lucy Lum,Gathsaurie Neelika Malavige,Steven McGloughlin,Bharath Kumar Tirupakuzhi Vijayaraghavan,Laura Merson,Daniel Munblitthe DEN-CORE Study Group
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e231
PERSONAL VIEW（个人观点）
32
Breaking the under-reporting cycle for zoonotic diseases in low-income and middle-income countries through national-level integration of community-based surveillance and response: insights from Cameroon, Chad, Côte d’Ivoire, and Mali
通过国家层面整合社区监测和响应，打破低收入和中等收入国家人畜共患病报告不足的循环：来自喀麦隆、乍得、科特迪瓦和马里的见解
Katherine E L Worsley-Tonks,Mahamat Fayiz Abakar,Zanan Coulibaly,Marie Paulette Deya-Yang,Linda Esso,Jean Marc Kameni Feussom,Vessaly Kallo,Zakaria Keita,Monique Lechenne,Magloire Tchamba Kombou,Inès Emah Manda,Christiane Mangou,Stephanie Mauti,Aime Gilert Mbonda Noula,Rodrigue Poueme Namegni,Perrine Parize,Mathurin Cyrille Tejiokem,Isaac Tiembre,Abdallah Traoré,Jakob Zinsstag,Hervé Bourhy
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e245
GRAND ROUND（大查房）
33
Paediatric case of invasive group A streptococcal necrotising myositis: diagnostic challenges and lessons learned
儿童侵袭性A组链球菌坏死性肌炎病例：诊断挑战和经验教训
Suraya Yusuf,Michael James Carter,Jenny Woodruff,Peter Kalu,Justin Conrad Rosen Wormald,Claire Sethu
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e259
CLINICAL PICTURE（临床图像）
34
Bullous haemorrhagic cellulitis caused by Escherichia coli in a patient with cirrhosis
肝硬化患者由大肠杆菌引起的大疱性出血性蜂窝织炎
Irene Rivera-Ruiz,Paloma Elma Alañón-Martínez,Elisa Vidal-Verdú
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e268
THE LANCET Infectious Diseases. Volume 26Number 5
柳叶刀·传染病学26卷 5期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
How are vaccine recommendations made?
疫苗建议是如何制定的？
The Lancet Infectious Diseases
The Lancet Infectious Diseases. May 2026，Vol 26(5)：p439
COMMENT（述评）
2
First efficacy evidence for a multistage malaria vaccine targeting infection and transmission
针对感染和传播多阶段的疟疾疫苗首次显示出有效性证据
Gemma Moncunill,Carlota Dobaño
The Lancet Infectious Diseases. May 2026，Vol 26(5)：p440
3
Lassa viral dynamics: implications for missed diagnosis
拉沙病毒动态：对漏诊的影响
Chinwe Lucia Ochu,William Douglas Evans
The Lancet Infectious Diseases. May 2026，Vol 26(5)：p441
4
Nirsevimab over two RSV seasons: do the findings align with expectations?
两个呼吸道合胞病毒（RSV）季节中Nirsevimab的应用情况：研究结果是否符合预期？
Corinne Levy,Robert Cohen
The Lancet Infectious Diseases. May 2026，Vol 26(5)：p443
5
Improving antimalarial therapeutic efficacy studies
提高抗疟治疗疗效研究的质量
Philip J Rosenthal
The Lancet Infectious Diseases. May 2026，Vol 26(5)：p444
6
The case for routine patient review in long COVID research
在长期新冠研究中开展常规患者评估的理由
Letícia Soares,C H Romatowski,Gina Assaf,Chloé de Canson
The Lancet Infectious Diseases. May 2026，Vol 26(5)：p446
CORRESPONDENCE（读者来信）
7
When mpox is not mpox: varicella and measles in DR Congo
当猴痘并非猴痘时：刚果民主共和国的水痘和麻疹病例
Levi Bugwaja,Nathan Banzi,Trust Faraja Mukika,Patrick Kazuba Bugale,Patrick Musole Bugeme,Emmanuel Biragi Nzenze,Heshima Lajeri Nzirimo,Salomon Mashupe Shangula,Justin Bengehya,Willy Kasi,Krutika Kuppalli,Camille Escadafal,Daniel Mukadi-Bamuleka,Jackie Knee,Jules Jackson,Elizabeth C Lee,Andrew S Azman,Espoir Bwenge Malembaka
The Lancet Infectious Diseases. May 2026，Vol 26(5)：e209
8
Mpox virus in human breastmilk and tecovirimat pharmacokinetics: implications for postnatal transmission
人乳中的猴痘病毒及特考韦瑞药代动力学：对产后传播的影响
Francesca Colavita,Massimo Tempestilli,Silvia Meschi,Carla Pittini,Martina Rueca,Giuseppe Sberna,Fabrizio Carletti,Simone Lanini,Silvia Cammisa,Giulia Paviotti,Lorenza Driul,Miriam De Vito,Cesare Ernesto Maria Gruber,Marco Cotrufo,Eleonora Cimini,Valentina Mazzotta,Andrea Antinori,Carlo Tascini,Fabrizio Maggi,Licia Bordi
The Lancet Infectious Diseases. May 2026，Vol 26(5)：e211
CORRECTIONS（更正）
9
Correction to Lancet Infect Dis 2026; 26: 522–34
对《柳叶刀-传染病》2026年第26卷第522–34页的更正
The Lancet Infectious Diseases. May 2026，Vol 26(5)：e213
NEWSDESK（新闻台）
10
New WHO recommendations for tuberculosis diagnosis
世卫组织新的结核病诊断建议
Timothy Jesudason
The Lancet Infectious Diseases. May 2026，Vol 26(5)：e214
11
New report assesses antimicrobial pipeline
新报告评估抗菌药物研发管线
Manjulika Das
The Lancet Infectious Diseases. May 2026，Vol 26(5)：e215
12
Meningitis B outbreak in England
英格兰B型脑膜炎暴发
Tony Kirby
The Lancet Infectious Diseases. May 2026，Vol 26(5)：e216
13
WHO reports on health of migrants and refugees
世卫组织发布移民和难民健康报告
Talha Burki
The Lancet Infectious Diseases. May 2026，Vol 26(5)：e217
14
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. May 2026，Vol 26(5)：e218
OBITUARY（讣告）
15
Christian C Patrick
克里斯蒂安·C·帕特里克
Sanjeet Bagcchi
The Lancet Infectious Diseases. May 2026，Vol 26(5)：p448
PROFILE（人物简介）
16
Eizo Takashima—developing a new class of malaria vaccines
高石荣三——开发新型疟疾疫苗
Tony Kirby
The Lancet Infectious Diseases. May 2026，Vol 26(5)：p449
MEDIA WATCH（媒体观察）
Book（书籍）
17
Feminism and the AIDS epidemic
女权主义与艾滋病流行
Charlotte Day
The Lancet Infectious Diseases. May 2026，Vol 26(5)：p450
ARTICLES（论著）
18
Efficacy of ProC6C-AlOH/Matrix-M against Plasmodium falciparum infection and mosquito transmission: a phase 2, randomised, controlled human malaria infection study
ProC6C-AlOH/Matrix-M预防恶性疟原虫感染和蚊子传播的有效性：一项2期随机对照人体疟疾感染研究
Mamady Kone,Jordan Plieskatt,Moussa Thienta,Bourama Kamate,Ebenezer A Ofori,Markus Gmeiner,Bayaya Haidara,Moussa B Kanoute,Bakary Traore,Ousmane A Poudiouguo,Hawa S Bayogo,Ibrahim Diarra,Karim Bengaly,Amatigue Zeguime,Daman Sylla,Adama Sacko,Stephen L Hoffman,Matthew B B McCall,Michael Theisen,Issaka Sagaraon behalf of the ProC6C Study Group
The Lancet Infectious Diseases. May 2026，Vol 26(5)：p451
19
The effectiveness of long-lasting spatial repellent emanators against malaria in humanitarian crisis settings in northern Nigeria: a two-arm pragmatic, open-label, controlled trial
长效空间驱蚊剂在尼日利亚北部人道主义危机环境中预防疟疾的有效性：一项双臂实用、开放标签、对照试验
Richard James Allan,Ramona Scherrer,Sara Estecha-Querol,David Weetman,Laura Paris,Umar Ba'abba Goni,Fatima Idris Abdulhamid,Blaise Nfornuh Alenwi,Sajjad Ahmad,Chad L Cross,Garba Mohammed Ashir,Mala Waziri,Godwin Ntadom,Louisa Alexandra Messenger
The Lancet Infectious Diseases. May 2026，Vol 26(5)：p464
20
Lassa fever symptomatology, viral dynamics, and host immune response (PREPARE): a prospective, observational cohort study in Liberia
拉沙热症状、病毒动态和宿主免疫反应（PREPARE）：利比里亚一项前瞻性观察队列研究
David A Wohl,Carwolo Pewu,Chanhwa Lee,Emmanuel Kerkula,Martha Gayflowu,Nukal Doetein,Katie R Mollan,Taylor J Krajewski,Becky Straub,Alfred Flomo,Amara Fofana,Stanley Kerkula,Thomas Sumo,Alexander Sampson,Samuel Vouh,Fred Flomo,McKenzie A Colt,Thomas Remont,Eleanor Rose Watts,Marta Zizek,Catherine Nimely,Minnie Ricks,Jefferson Sibley,William A Fischer II
The Lancet Infectious Diseases. May 2026，Vol 26(5)：p475
21
Immunogenicity and safety of a group B Streptococcus vaccine (GBS-AlpN) in pregnant women and their infants: a phase 2, multicentre, observer-blind, randomised, placebo-controlled study
B群链球菌疫苗（GBS-AlpN）在孕妇及其婴儿中的免疫原性和安全性：一项2期、多中心、观察者设盲、随机、安慰剂对照研究
Paul T Heath,Ntokozo Zuma-Gwala,Rikke Bek Helmig,Elizea Horne,Anette Kjærbye-Thygesen,Mie Korslund Wiinblad Crusell,Maphoshane Nchabeleng,Renate Strehlau,Mohammed R Khalil,Christine E Jones,Jorne Biccler,Jeannett Dimsits,Bengt Johansson-Lindbom,Per B Fischer,Lidia Oostvogels,Shabir A Madhion behalf of the MVX0004 study group
The Lancet Infectious Diseases. May 2026，Vol 26(5)：p486
22
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial
单剂量口服减毒霍乱活疫苗PanChol的安全性和免疫原性：一项1a期、双盲、随机、安慰剂对照试验结果
Deborah R Leitner,Stephen R Walsh,Masataka Suzuki,Michaël Desjardins,Alisse Hannaford,Amy C Sherman,Hannah Levine,Lena Carr,Elliot Hammerness,Akina Osaki,Emily Sullivan,Bryan Wang,George I Balazs,Jun Bai Park Chang,Damien M Slater,Nirajan Puri,Carole J Kuehl,Wilbur H Chen,Jason B Harris,Steven Piantadosi,Lindsey R Baden,Matthew K Waldoron behalf of the PanChol study group
The Lancet Infectious Diseases. May 2026，Vol 26(5)：p497
23
Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial
晚期艾滋病患者使用整合酶抑制剂与蛋白酶抑制剂治疗（LAPTOP）：一项多国、随机、开放标签、非劣效性试验
Georg M N Behrens,Lambert Assoumou,Geoffroy Liegeon,Andrea Antinori,Rafael Micán,Francesco G Genderini,Frank A Post,Jürgen K Rockstroh,Lisa Hamzah,Pere Domingo,Adrian Curran,Montserrat Laguno,Carl Fletcher,Jack Moody,Anton Pozniakon behalf of the NEAT-ID Foundation,and LAPTOP Study Team
The Lancet Infectious Diseases. May 2026，Vol 26(5)：p510
24
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study
在西班牙加利西亚婴儿中进行Nirsevimab普遍预防，对横跨两个呼吸道合胞病毒季节的医院和初级保健结果的影响（NIRSE-GAL）：一项基于人群的前瞻性观察研究
Josefina L Razzini,Iago Giné-Vázquez,Jing Jin,María-Isolina Santiago-Pérez,Olaia Pérez-Martínez,María-Teresa Otero-Barrós,Nuria Suárez-Gaiche,Rolf Kramer,Leticia Platero-Alonso,Rosa-María Álvarez-Gil,Olga-María Ces-Ozores,Victoria Nartallo-Penas,Susana Mirás-Carballal,Marta Piñeiro-Sotelo,Juan-Manuel González-Pérez,Carmen Rodríguez-Tenreiro-Sánchez,Ángela Manzanares-Casteleiro,Ana Dacosta-Urbieta,Cintia Álvarez-Smith,Irene Rivero-Calle,Antonio Salas,Carmen Durán-Parrondo,Narmeen Mallah,Federico Martinón-Torres
The Lancet Infectious Diseases. May 2026，Vol 26(5)：p522
25
Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study
CRS3123治疗成人艰难梭菌感染初次发作或首次复发的安全性和有效性：一项2期、随机、双盲、多中心、万古霉素对照研究
Thomas Louie,Wendy Ribble,Louis Boccumini,Katherine Johnson,Mary A De Groote,Joshua Day,Clifford Mason,Xicheng Sun,Jane Freeman,Kenan Gu,Glenn Tillotson,Mark H Wilcox,Nebojsa Janjic,Thale C Jarvis,Seema U Nayak,Urs A Ochsner,Jon B Bruss
The Lancet Infectious Diseases. May 2026，Vol 26(5)：p535
REVIEW（综述）
26
The Emerging Resistance Index: tracking early resistance to new antibiotics
新兴耐药指数：追踪新抗生素的早期耐药性
Jacopo Garlasco,Fabiana Arieti,Matteo Morra,Maela Tebon,Diego Ortiz,Maria Diletta Pezzani,Karin Odoj,Federica Manco,Alessandro Cassini,Stephan Harbarth,Elisabeth Presterl,Biljana Carevic,Gunnar Kahlmeter,Karin Thursky,Paola Morelli,Stefan Hagel,Alessia Savoldi,Evelina Tacconelli
The Lancet Infectious Diseases. May 2026，Vol 26(5)：e219
27
Kyasanur Forest disease: an emerging arboviral threat
基萨努尔森林病：一种新兴的虫媒病毒威胁
Neha Pandey,Sunit K Singh
The Lancet Infectious Diseases. May 2026，Vol 26(5)：e228
PERSONAL VIEW（个人观点）
28
Reconsidering the clinical assessment of resistance to slowly eliminated antimalarial drugs in high-transmission settings
重新考虑高传播地区对缓慢消除抗疟药物耐药性的临床评估
Nicholas J White,James A Watson
The Lancet Infectious Diseases. May 2026，Vol 26(5)：e240
GRAND ROUND（大查房）
29
Safe delivery of intensive care for Marburg virus disease in Rwanda
卢旺达安全实施马尔堡病毒病重症监护
Eric Seruyange,Ernest Nahayo,François Xavier Uwimana,Joseph Biramahire,Fidele Hakorimana,Menelas Nkeshimana,David Turatsinze,Anselme Bizimana,Hassan Mugabo,Bosco Burakari,Ryan P Westergaard,Louise Mwiseneza,Nicholas Niyigaba,Jean Pierre Sibomana,Tsion Firew,Lambert Ingabire,Gaston Nyirigira,Etienne Kayigi,Evariste Mushuru,Marie Grace Niwemuhoza,Marie Grace Niyonizeye,Gisele Isingizwe,Josué Bongwa Rwibutso,Jean Pierre Nzabana,Gentil Semahoro Ndayishimiye,Déo Kimalarungu Ntakambirwa,Serge Kazindu,Halifa Ndayisabye,Eric Remera,Leon Mutesa,Jean Paul Rwabihama,Muhammed Semakula,Robert Fowler,Ruggero Giuliani,Jacob Goldberg,Frederique Jacquerioz,Janet Diaz,Amanda Rojek,Claude M Mambo,Yvan Butera,Sabin Nsanzimana,Elizabeth O Moreton,Thomas E Fletcher,William A Fischer 2nd,Théogène Twagirumugabe
The Lancet Infectious Diseases. May 2026，Vol 26(5)：e248
CLINICAL PICTURE（临床图像）
30
Disseminated fusariosis arising from onychomycosis in a haematopoietic transplant recipient
造血干细胞移植受者甲癣引发的播散性镰刀菌病
Wouter A A de Steenhuijsen Piters,Man Wai Tang,Inge A H van den Berk,M E Baarsma,Karin van Dijk
The Lancet Infectious Diseases. May 2026，Vol 26(5)：e256
THE LANCET Infectious Diseases. Volume 26Number 6
柳叶刀·传染病学26卷 6期
https://www.thelancet.com/journals/laninf/issue/current
Editorial（社论）
1
The value of infectious disease conferences
传染病会议的价值
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p549
Comment（述评）
2
From emergency to integration: research as the bridge in mpox control
从紧急应对到整合：作为猴痘防控的桥梁的研究
Yap Boum,Mosoka Fallah,Michel Muteba,Henry Kyobe Bosa,Kyeng Mercy,John Misaki Wayengera,Bruce Kirenga,John Otshudiema,Placide Mbala,Marie-Roseline Belizaire,Ngashi Ngongo,Jean Kaseya
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p550
3
Strength of ATLAS or lady luck in a sepsis management trial?
脓毒症治疗试验，是ATLAS的力量还是幸运女神的眷顾？
Mojdeh Azimi,Dick Menzies
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p552
4
Reimagining radical cure for Plasmodium vivax
重新构思间日疟原虫的根治方案
Pyae Linn Aung,Liwang Cui
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p554
5
Does BA.3.2 epidemiology imply a change in SARS-CoV-2 evolution?
BA.3.2的流行病学是否意味着SARS-CoV-2进化方向的改变？
Lu Zhang,Markus Hoffmann,Stefan Pöhlmann
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p555
Correspondence（读者来信）
6
Concerns regarding study of spatial emanators for malaria control
关于研究用于疟疾防控的空间传播因子的担忧
John Bradley,Richard Hayes,Peter G Smith,Immo Kleinschmidt
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e209
7
Concerns regarding study of spatial emanators for malaria control – Authors' reply
关于疟疾防控中空间散发器研究的关切——作者回复
Richard James Allan,Chad L Cross,Louisa Alexandra Messenger
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e210
Newsdesk（新闻台）
8
Bangladesh launches measles vaccine drive amid outbreak
孟加拉国在疫情期间启动麻疹疫苗接种运动
Samaan Lateef
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e211
9
Tecovirimat no longer approved for mpox in the EU
欧盟不再批准替可韦利马用于猴痘治疗
Sanjeet Bagcchi
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e212
10
Highlights of ESCMID Global 2026
2026年ESCMID全球大会亮点
Syeda Saleha Hassan
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e213
11
Global vaccination drive reaches 18.3 million children
全球疫苗接种运动已覆盖1830万儿童
Timothy Jesudason
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e214
12
Israel accused of using “water as a weapon” in Gaza
以色列被指控在加沙"以水为武器"
Talha Burki
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e215
13
Research in brief
研究简报
Priya Venkatesan
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e216
Obituary（讣告）
14
James Phillip Luby
詹姆斯·菲利普·卢比
Sanjeet Bagcchi
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p558
Profile（人物介绍）
15
Daniela Hozbor—raising the bar for pertussis vaccines
丹妮拉·霍兹博尔——提升百日咳疫苗标准
Tony Kirby
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p559
Media Watch（媒体观察）
Book（书籍）
16
Building bridges
搭建桥梁
Hollie Sherwood-Martin
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p560
Articles（论著）
17
Safety of MVA-BN vaccine in health-care personnel in DR Congo: a prospective cohort study
MVA-BN疫苗在刚果（金）医务人员中的安全性：前瞻性队列研究
Faisal S Minhaj,Anna Mandra,Béatrice U Nguete,Toutou Likafi,Gaston Kokola,Stephanie Tran,Jordan L Kennedy,Benjamin Monroe,Christine M Hughes,Taina Joseph,Marissa K Person,Michael B Townsend,Panayampalli S Satheshkumar,Joelle Kabamba,Mary G Reynolds,Agam K Rao,Dorah Kasongo,Patricia A Yu,Yon Yu,Robert Shongo Lushima,Didine Kaba,Brett Petersen,Andrea M McCollum
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p561
18
Immunogenicity and safety of MVA-BN vaccine administered 5 years after a two-dose primary series in DR Congo: a prospective cohort study
两剂基础免疫后5年接种MVA-BN疫苗的免疫原性和安全性：刚果（金）前瞻性队列研究
Lalita Priyamvada,Faisal S Minhaj,Toutou Likafi,Elisabeth Pukuta,Elisabeth Muyamuna,William C Carson,Margaret Moriarty,Sergio Rodriguez,Taina Joseph,Joelle Kabamba,Gaston Kokola,Robert Shongo Lushima,Jean-Jacques Muyembe-Tamfum,Christine M Hughes,Brett W Petersen,Yon Yu,Agam Rao,Andrea M McCollum,Didine K Kaba,Beatrice U Nguete,Panayampalli S Satheshkumar,Michael B Townsend
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p571
19
A combined ELISA for infection-induced and vaccine-induced mpox antibodies during the clade Ib outbreak in Rwanda: an observational, cross-sectional, clinical validation study
伊布分支疫情期间卢旺达猴痘感染诱导和疫苗诱导抗体联合ELISA检测：观察性横断面临床验证研究
Jenny Clarke,Herve Semukunzi,Sian E Faustini,Jennifer L J Heaney,Hin Fai Kwok,Jean Marie Vianney Uwimana,Karishma Gokani,Gilbert Rukundo,Jean Pierre Musabyimana,Prosper Ingabire,Leopold Bitunguhari,Jean de Dieu Harelimana,Alex G Richter,Claude M Muvunyi,Christopher A Greenand the MpoxCARE Study Team
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p581
20
Case presentation of patients hospitalised with mpox (subclade Ib/2023sh) including children, adolescents, and adults in South Kivu, Democratic Republic of the Congo: an observational cohort study
刚果（金）南基伍省住院猴痘患者（伊布亚分支/2023sh）病例报告，包括儿童、青少年和成人：观察性队列研究
Luis Flores Girón,Gustavo Sganzerla Martinez,Baganda Ntahuma Daniel,Alfred Kesheni Bisimwa,Nkonzi Pacific,Georges Assumani Martin,Jean Christian Amini Kabwana,Anuj Kumar,Ali Toloue Ostadgavahi,Mansi Dutt,Kawaya Lusante Bénite,Mangura Hamuli Damien,Christian Gortázar,Bahaa Abu-Raya,Alyson A Kelvin,Kaleme Kiswele Prince,David J Kelvin
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p590
21
Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2×2 factorial, superiority trial
坦桑尼亚和乌干达HIV相关脓毒症的即时或高剂量抗结核治疗（ATLAS）：一项3期、开放标签、随机对照、2×2析因、优效性试验
Scott K Heysell,Stellah G Mpagama,Edwin Nuwagira,Bibie Said,Mark Conaway,Megan Null,Tania A Thomas,David R Boulware,Eva Otoupalova,Rinah Arinaitwe,Rhina Mushagara,Louisa Edwards,Peter Buzaare,Athumani M Ngoma,Davis Muganzi,Geofrey Gidoi,Samuel Jjunju,Antony Gulinja,Arestaricky G Rimoy,Fredrick C Mwita,Jeremiah Kidola,Oscar Atwiine,David Ocaaki,Dalton K Munyambalu,Jie Liu,Lucas Ampaire,Buliga Mujaga,Prakruti Rao,Alphonce Liyoyo,Margaretha Sariko,Conrad Muzoora,Christopher C Moore
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p601
22
Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial
7天高剂量伯氨喹和单剂量他芬诺奎与14天低剂量伯氨喹治疗间日疟原虫疟疾的有效性和安全性（EFFORT）：一项多中心、开放标签、随机对照、优效性试验
Tamiru Shibiru Degaga,Ayodhia Pitaloka Pasaribu,Rupam Tripura,Najia Ghanchi,Megha Rajasekhar,Bipin Adhikari,Benedikt Ley,Samuel Alemu Bamboro,Fareeha Abdul Jabbar,Nurfadhilah Hasibuan,Tedla Teferi Tego,Shane Zehra,Bushra Qurashi,Hellen Mnjala,Grant Lee,Peixuan Li,Abdul Momin Kazi,Widaya Safitri,Yulita Yulita,Dedi Sahat Parningotan Siagian,Deni Syahputra,Halik Hadi,Taj Muhammad,Amna Ibrahim,Nasreen Syed,Khuda Dost,Agatha Mia Puspitrasari,Pinkan Pertiwi Kariodimedjo,Anjana Rai,Angela Rumaseb,Edwin Sutanto,Mom Ean,Asia Khan,Meas Sokha,Robert James Commons,Sophie Weston,Rintis Noviyanti,Tom Peto,James J Callery,Umair Ali,Tariq Mehmood,Arjen Dondorp,Angela Devine,Ery Setiawan,Muthoni Mwaura,Sarah Cassidy-Seyoum,Rodas Temesgen,Dagimawie Tadesse Abate,Eyerusalem Beyene Erjabo,Geremew Gashaw Gessa,Fitsum Getahun Kiros,Muhammad Imran Usmani,Ali Raza,Adugna Woyessa,Asrat Hailu,Julie A Simpson,Amalia Karahalios,Mohammad Asim Beg,Lorenz von Seidlein,Lek Dysoley,Sarah Auburn,Ric N Price,Kamala Thriemer
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p614
23
Efficacy of ETVAX, a vaccine against enterotoxigenic Escherichia coli-positive diarrhoea in Gambian children: a double-blind, randomised, placebo-controlled, phase 2b trial
ETVAX疫苗对冈比亚儿童产肠毒素大肠杆菌阳性腹泻的有效性：一项双盲、随机、安慰剂对照、2b期试验
M Jahangir Hossain,Fatou Secka,Lady C Sanyang,Raifu Taiwo,Emmanuel C Okoh,Olubunmi A Olubiyi,Mbemba Drammeh,Emmanuel U Richard,Ahmed D Balami,Mama Drammeh,Samba Juma Jallow,Bakary Sonko,Paticia Ezedimbu-Michael,Jacinta Obiaduo,Ousman Secka,Joanna Kaim,Björn Sjöstrand,Agneta Lissmats,Nils Carlin,Umberto D'Alessandro,Ann-Mari Svennerholm,Thomas F Wierzba
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p627
24
Safety and immunogenicity of a conjugate vaccine candidate against Salmonella enterica serovars Typhi and Paratyphi A in healthy adults in Europe: a phase 1 randomised controlled trial
伤寒和副伤寒A沙门氏菌结合疫苗候选物在欧洲健康成人中的安全性和免疫原性：1期随机对照试验
Ilse De Coster,Mohammad AbdelGhany,Eleanna Sarakinou,Chiara Fineschi,Elisa Marchetti,Rita La Gaetana,Simona Nigro,Martina Carducci,Luisa Massai,Valentino Conti,Omar Rossi,Giulia Luna Cilio,Alimamy Serry-Bangura,Pietro Tessitore,Pierre Van Damme,Kanchanamala Withanage,Francesca Micoli,Francesco Berlanda Scorza,Simona Rondini,Usman N Nakakana,Ashwani Kumar Arora
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p638
Review（综述）
25
British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases: 2025 update
英国医学真菌学会严重真菌病诊断最佳实践建议：2025年更新
Silke Schelenz,Alireza Abdolrasouli,Darius Armstrong-James,H Ruth Ashbee,Richard Barton,Tihana Bicanic,Andy Borman,Lottie Brown,Chris Eades,Laura Ferreras-Antolin,Rebecca Gorton,Ronan McMullan,Iain Page,Nelun Perera,Riina Rautemaa-Richardson,Johannes Wagener,P Lewis White,David W Denning
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e217
26
Empirical and targeted antimicrobial therapy in patients with febrile neutropenia and haematological malignancy or after haematopoietic cell transplantation: recommendations from the 10th European Conference on Infections in Leukaemia
血液系统恶性肿瘤或造血干细胞移植后发热性中性粒细胞减少患者的经验性和目标性抗菌治疗：第10届欧洲白血病感染会议建议
Dina Averbuch,Yuri Vanbiervliet,Francesco Baccelli,Malgorzata Mikulska,Dionysios Neofytos,Carolina Garcia-Vidal,Manuela Aguilar-Guisado,Nicole Blijlevens,Patricia Munoz,Catherine Cordonnier,Murat Akova,Thierry Calandra
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e232
Personal View（个人观点）
27
Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development
结核病治疗的未来保障：药物与耐药性检测协同开发框架
Francesca Saluzzo,Seda Yerlikaya,Susan Elizabeth Dorman,Kathleen Eisenach,Maha Reda Farhat,Nazir Ismail,Christian Lienhardt,Timothy M Walker,Fatima Jones,Ana Yepes,Adam Penn-Nicholson,Morten Ruhwald,Bavesh Kana,Claudia Maria Denkinger,Daniela Maria Cirillo
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e248
Grand Round（大查房）
28
Below-knee amputation following osteomyelitis from multidrug-resistant Stenotrophomonas maltophilia in a diabetic foot ulcer
糖尿病足溃疡中多重耐药嗜麦芽窄食单胞菌骨髓炎致膝下截肢
Alejandro Arbona-Lampaya,Ricardo A Pérez-Ojeda,Melanie Santos-Marrero,Adrián Pérez-Aybar
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e257
Clinical Picture（临床图像）
29
Severe inguinal bubo and haemorrhagic exanthem in autochthonous clade Ib mpox
本土伊布分支猴痘导致的严重腹股沟淋巴结肿大和出血性皮疹
Patrick E Obermeier,Philipp Schulz,Hartmut Stocker,Ingo Ochlast,Livia Schrick,Annika Brinkmann,Pascal Migaud
The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e266
2026-05-31
·中财网
原标题:泰恩康:关于控股子公司CKBA乳膏玫瑰痤疮适应症IIa期临床试验完成全部受试者入组暨提前启动IIb期临床试验的公告
药品名称CKBA乳膏注册分类化学药品1类适应症玫瑰痤疮申办单位江苏博创园生物医药科技有限公司主要试验机构四川大学华西医院二、临床试验相关情况玫瑰痤疮是一种好发于面中部，主要累及面部血管、神经及毛囊皮脂腺单位的慢性复发性炎症性疾病。流行病学研究显示，中国人群玫瑰痤疮的患病率3.36%~3.48%。玫瑰痤疮作为损容性皮肤病，焦虑、抑郁等负性情绪在玫瑰痤疮患者中非常普遍，患者治疗意愿迫切。玫瑰痤疮发病机制及诱因尚未十分明确，故其治疗是一个复杂的过程，患者通常需要长期维持治疗以控制症状。近年来，FDA获批的治疗玫瑰痤疮的药物如伊维菌素乳膏、盐酸米诺环素缓释胶囊等均为老药新用，临床观察显示，仍存在疗效有限、耐受性不佳、复发率高等未被满足的治疗需求。截至目前，国内尚未有治疗玫瑰痤疮的1类创新药获批上市，迫切需要开发具有安全性高、疗效明确且副作用小的创新药物，以满足临床需求。CKBA是上海交通大学医学院附属第一人民医院王宏林团队从乳香天然产物修饰而来的创新小分子，是一种全新靶点（First-in-Class，靶向ACC1/MFE-2）的免疫调节剂，而非传统的强效免疫抑制剂，是全球首个靶向T细胞脂肪酸代谢通路的创新小分子，拥有中国、美国、欧盟和日本等全球自主知识产权。CKBA乳膏于2025年9月收到国家药品监督管理局签发的玫瑰痤疮II/III期无缝适应性临床试验批准通知书，获批后公司启动CKBA乳膏治疗丘疹脓疱型玫瑰痤疮的IIa期临床试验，并于2026年3月25日完成首例受试者入组。本次IIa期临床试验采取单中心、开放性、单臂设计，在四川大学华西医院开展，评价1.5%CKBA乳膏治疗中度至重度丘疹脓疱型玫瑰痤疮的有效性和安全性，主要临床终点指标为治疗16周时炎性病灶计数（ILC）相较基线的变化以及治疗16周时研究者整体评估(IGA)评分为0或1分的受试者比例，计划入组15例病人，近日已完成全部15例受试者入组工作。本次IIa期临床试验初步结果表明，已完成4周随访的受试者（n=7）炎性皮损计数（ILC）显著减少（p<0.05），平均减少13.1个（95%CI:-26.2~-0.1）；其中71.4%（5/7）的受试者实现研究者整体评估（IGA）评分同步改善。已完成8周随访的受试者（n=5）炎性皮损计数（ILC）均呈持续下降趋势（p<0.05），平均减少14.1个（95%CI:-25.7~-3.1），且有1例（20.0%）已达到临床终点指标。患者自我评价较基线平均改善27.4%（95%CI:-46.6%~-8.1%），无严重不良反应发生，患者依从性高。提示1.5%CKBA乳膏具有良好的短期疗效与长期治疗潜力以及优异的安全性。鉴于目前CKBA乳膏玫瑰治疗痤疮适应症获得积极的IIa期临床试验初步数据，公司拟提前启动IIb期临床试验，四川大学华西医院为本研究的组长单位，目前已完成IIb期临床试验方案的制定、临床试验研究机构的初步筛选等工作。公司将严格遵照相关要求，高质高效、加速推进临床试验工作。三、对公司的影响及风险提示CKBA乳膏玫瑰痤疮适应症IIa期临床试验相关数据仅为初步统计分析结果，完整的有效性和安全性结论以最终的临床总结报告为准。公司预计该项目短期内对公司财务状况、经营业绩不会产生重大影响。由于创新药开发具有周期长、投入大的特点，存在推进及研发效果不达预期的风险，CKBA乳膏的临床试验进度、审评和审批的结果以及未来产品市场竞争格局都具有一定的不确定性。药品能否获批上市以及获批上市的时间、上市后的生产和销售情况存在不确定性。公司将按规定对上述项目后续进展情况履行信息披露义务，敬请投资者注意投资风险。特此公告。广东泰恩康医药股份有限公司董事会2026年5月31日 中财网
2026-05-31
.hx_pdf_tb, .hx_pdf_container {
border-collapse: collapse;
margin: 10px auto;
min-width: 90%;
}
.hx_pdf_tb td, .hx_pdf_tb th {
border: 1px solid;
}
.hx_pdf_container td, .hx_pdf_container th {
border: 1px dashed;
}
.hx_pdf_container {
border: 2px dashed black;
margin: 10px;
}
.hx_pdf_container .hx_pdf_container {
border: 2px solid blue;
}
.hx_pdf_container .hx_pdf_container .hx_pdf_container {
border: 2px solid red;
}
.hx_pdf_p {
text-indent: 2em;
margin: 10px;
}
td>.hx_pdf_p {
text-indent: 1em;
margin: 7px;
}
.hx_img_wrap {
text-align: center;
}
.ft0 {
font-family: MLJNAR+SimSun;
font-size: 19.200000;
font-weight: 0;
color: black;
font-style: inherit
}
.ft1 {
font-family: DGFMOR+TimesNewRomanPSMT;
font-size: 19.200000;
font-weight: 0;
color: black;
font-style: inherit
}
.ft2 {
font-family: MLJNAR+SimSun;
font-size: 24.000000;
font-weight: bold;
color: black;
font-style: inherit
}
.ft3 {
font-family: CLGUCU+TimesNewRomanPS-BoldMT;
font-size: 24.000000;
font-weight: bold;
color: black;
font-style: inherit
}
.ft4 {
font-family: MLJNAR+SimSun;
font-size: 19.200000;
font-weight: bold;
color: black;
font-style: inherit
}
.ft5 {
font-family: CLGUCU+TimesNewRomanPS-BoldMT;
font-size: 19.200000;
font-weight: bold;
color: black;
font-style: inherit
}
证券代码：301263
证券简称：泰恩康
公告编号：2026-053
广东泰恩康医药股份有限公司
关于控股子公司CKBA乳膏玫瑰痤疮适应症IIa期临床试验完成全部受试者入组暨提前启动IIb期临床试验的公告
本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或者重大遗漏。
近日，广东泰恩康医药股份有限公司（以下简称“公司”）控股子公司江苏博创园生物医药科技有限公司（以下简称“博创园”）自主研发的1类创新药CKBA乳膏玫瑰痤疮适应症IIa期临床试验完成全部受试者入组，获得积极有效的初步试验数据，公司拟提前启动IIb期临床试验。现将相关情况公告如下：
一、项目主要内容
药品名称CKBA乳膏注册分类化学药品1类适应症玫瑰痤疮申办单位江苏博创园生物医药科技有限公司主要试验机构四川大学华西医院
二、临床试验相关情况
玫瑰痤疮是一种好发于面中部，主要累及面部血管、神经及毛囊皮脂腺单位的慢性复发性炎症性疾病。流行病学研究显示，中国人群玫瑰痤疮的患病率3.36%~3.48%。玫瑰痤疮作为损容性皮肤病，焦虑、抑郁等负性情绪在玫瑰痤疮患者中非常普遍，患者治疗意愿迫切。玫瑰痤疮发病机制及诱因尚未十分明确，故其治疗是一个复杂的过程，患者通常需要长期维持治疗以控制症状。近年来，FDA获批的治疗玫瑰痤疮的药物如伊维菌素乳膏、盐酸米诺环素缓释胶囊等均为老药新用，临床观察显示，仍存在疗效有限、耐受性不佳、复发率高等未被满足的治疗需求。截至目前，国内尚未有治疗玫瑰痤疮的1类创新药获批上市，迫切需要开发具有安全性高、疗效明确且副作用小的创新药物，以满足临床需求。
CKBA是上海交通大学医学院附属第一人民医院王宏林团队从乳香天然产物修饰而来的创新小分子，是一种全新靶点（First-in-Class，靶向ACC1/MFE-2）的免疫调节剂，而非传统的强效免疫抑制剂，是全球首个靶向T细胞脂肪酸代谢通路的创新小分子，拥有中国、美国、欧盟和日本等全球自主知识产权。
CKBA乳膏于2025年9月收到国家药品监督管理局签发的玫瑰痤疮 II/III期无缝适应性临床试验批准通知书，获批后公司启动CKBA乳膏治疗丘疹脓疱型玫瑰痤疮的IIa期临床试验，并于2026年3月25日完成首例受试者入组。
本次IIa期临床试验采取单中心、开放性、单臂设计，在四川大学华西医院开展，评价1.5%CKBA乳膏治疗中度至重度丘疹脓疱型玫瑰痤疮的有效性和安全性，主要临床终点指标为治疗16周时炎性病灶计数（ILC）相较基线的变化以及治疗16周时研究者整体评估(IGA)评分为0或1分的受试者比例，计划入组15例病人，近日已完成全部15例受试者入组工作。
本次IIa期临床试验初步结果表明，已完成4周随访的受试者（n=7）炎性皮损计数（ILC）显著减少（p<0.05），平均减少13.1个（95%CI:-26.2~-0.1）；其中71.4%（5/7）的受试者实现研究者整体评估（IGA）评分同步改善。已完成8周随访的受试者（n=5）炎性皮损计数（ILC）均呈持续下降趋势（p<0.05），平均减少14.1个（95%CI:-25.7~-3.1），且有1例（20.0%）已达到临床终点指标。患者自我评价较基线平均改善27.4%（95%CI:-46.6%~-8.1%），无严重不良反应发生，患者依从性高。提示1.5%CKBA乳膏具有良好的短期疗效与长期治疗潜力以及优异的安全性。
鉴于目前CKBA乳膏玫瑰治疗痤疮适应症获得积极的IIa期临床试验初步数据，公司拟提前启动IIb期临床试验，四川大学华西医院为本研究的组长单位，目前已完成IIb期临床试验方案的制定、临床试验研究机构的初步筛选等工作。公司将严格遵照相关要求，高质高效、加速推进临床试验工作。
三、对公司的影响及风险提示
CKBA乳膏玫瑰痤疮适应症IIa期临床试验相关数据仅为初步统计分析结果，完整的有效性和安全性结论以最终的临床总结报告为准。公司预计该项目短期内对公司财务状况、经营业绩不会产生重大影响。
由于创新药开发具有周期长、投入大的特点，存在推进及研发效果不达预期的风险，CKBA乳膏的临床试验进度、审评和审批的结果以及未来产品市场竞争格局都具有一定的不确定性。药品能否获批上市以及获批上市的时间、上市后的生产和销售情况存在不确定性。
公司将按规定对上述项目后续进展情况履行信息披露义务，敬请投资者注意投资风险。
特此公告。
广东泰恩康医药股份有限公司
董事会
2026年5月31日
100 项与 伊维菌素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 玫瑰痤疮 | 美国 | 2014-12-19 | |
| 虱病 | 美国 | 2012-02-07 | |
| 疥疮 | 日本 | 2006-08-21 | |
| 蛔虫病 | 中国 | 2001-01-01 | |
| 丝虫性象皮病 | 中国 | 2001-01-01 | |
| 蛲虫病 | 中国 | 2001-01-01 | |
| 蠕虫病 | 中国 | 2001-01-01 | |
| 钩虫感染 | 中国 | 2001-01-01 | |
| 鞭虫病 | 中国 | 2001-01-01 | |
| 盘尾丝虫病 | 美国 | 1996-11-22 | |
| 类圆线虫病 | 美国 | 1996-11-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床2期 | 保加利亚 | 2022-03-25 | |
| 特应性皮炎 | 临床2期 | 加拿大 | 2016-11-01 | |
| 特应性皮炎 | 临床2期 | 加拿大 | 2016-11-01 | |
| 寻常痤疮 | 临床2期 | 加拿大 | 2016-04-25 | |
| 寻常痤疮 | 临床2期 | 加拿大 | 2016-04-25 | |
| 寻常痤疮 | 临床2期 | 法国 | 2016-04-25 | |
| 寻常痤疮 | 临床2期 | 法国 | 2016-04-25 | |
| 寻常痤疮 | 临床2期 | 德国 | 2016-04-25 | |
| 寻常痤疮 | 临床2期 | 德国 | 2016-04-25 | |
| 头虱 | 临床1期 | 美国 | 2017-03-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | 132 | 製膚衊繭繭繭淵餘壓衊(憲簾繭繭顧鑰構鹹醖醖) = 積淵遞窪願獵鹽獵壓淵 憲鬱糧餘醖窪餘選淵繭 (壓鏇淵觸繭顧憲齋鏇網 ) | 不佳 | 2026-05-07 | |||
製膚衊繭繭繭淵餘壓衊(憲簾繭繭顧鑰構鹹醖醖) = 顧鏇鹹網簾鏇製壓蓋範 憲鬱糧餘醖窪餘選淵繭 (壓鏇淵觸繭顧憲齋鏇網 ) | |||||||
临床2期 | 30 | (Control Group) | 窪選窪獵壓醖鹹壓範製(築構廠廠餘鹽鑰餘鬱繭) = 廠憲齋範糧觸齋觸獵襯 醖齋網艱遞糧構繭蓋蓋 (積憲壓壓餘遞構構齋夢, 獵鹽鹽夢夢鏇衊範憲廠 ~ 願膚積積網選鑰遞築憲) 更多 | - | 2026-03-27 | ||
digital interaction+Ivermectin (Digital Interaction Group) | 糧窪遞壓願獵衊夢簾齋 = 鑰鏇繭製獵窪衊選製繭 壓觸糧醖簾選憲憲積選 (簾範顧遞窪製獵範齋鏇, 鹹鹽壓憲廠膚窪繭衊淵 ~ 積衊襯選網淵顧憲蓋憲) 更多 | ||||||
临床3期 | 164 | (IA (Ivermectin + Albendazole)) | 鏇窪鹹鹹鑰蓋淵襯廠觸 = 蓋齋構夢憲鹹觸築鏇衊 積網廠製積鬱鬱廠鏇範 (餘獵鏇範獵網艱網觸網, 糧遞襯壓鏇獵鬱醖範鬱 ~ 鑰鏇廠範憲製獵襯齋鏇) 更多 | - | 2026-01-29 | ||
(MoxA (Moxidectin + Albendazole)) | 鏇窪鹹鹹鑰蓋淵襯廠觸 = 鹽醖醖觸簾衊構膚鑰憲 積網廠製積鬱鬱廠鏇範 (餘獵鏇範獵網艱網觸網, 鬱顧願製鏇蓋獵糧壓襯 ~ 醖簾衊鏇糧選簾鑰壓簾) 更多 | ||||||
临床3期 | 1,075 | 觸顧網選繭構網繭鑰鏇(襯顧襯糧衊製製襯觸壓) = 膚鏇遞壓餘衊蓋壓顧願 壓夢範願簾廠餘積選鏇 (糧觸獵選鹹醖窪積醖憲 ) 更多 | 不佳 | 2026-01-06 | |||
觸顧網選繭構網繭鑰鏇(襯顧襯糧衊製製襯觸壓) = 夢繭繭鹽遞蓋餘醖願艱 壓夢範願簾廠餘積選鏇 (糧觸獵選鹹醖窪積醖憲 ) 更多 | |||||||
临床3期 | 22,724 | 壓膚簾積網鏇蓋鏇築衊(廠窪遞鹽淵鏇網鹽夢廠): IRR = 1.29 (95.0% CI, 0.62 ~ 2.68) | 不佳 | 2025-12-01 | |||
临床3期 | 10,956 | (Arm A - Ivermectin 400) | 憲選獵襯鹹製糧顧蓋範 = 範膚餘鏇觸築廠窪鹹齋 鬱憲築衊顧遞網壓獵淵 (製鬱醖築醖糧顧醖壓鹽, 遞獵願糧鹹壓積網憲繭 ~ 範壓淵鹽憲鏇膚範膚製) 更多 | - | 2025-11-17 | ||
(Arm B - Fluvoxamine) | 憲選獵襯鹹製糧顧蓋範 = 憲鹽築鑰鹽遞餘憲廠鑰 鬱憲築衊顧遞網壓獵淵 (製鬱醖築醖糧顧醖壓鹽, 壓簾積獵糧積鑰鏇遞衊 ~ 築製壓壓繭壓壓網觸獵) 更多 | ||||||
临床2期 | 260 | Placebo Ivermectin ODT+Albendazole 400 mg Oral Tablet (Arm A: Ivermectin ODT Placebo & Albendazole) | 鬱簾鬱選鹽顧壓構顧構 = 糧鏇繭壓衊艱願膚衊鬱 衊糧網壓壓壓鬱淵簾窪 (餘廠壓構築膚願選鏇築, 顧蓋構餘齋鬱淵鑰網鹽 ~ 齋製觸鹽遞醖廠鏇廠齋) 更多 | - | 2025-09-22 | ||
(Arm B: Ivermectin ODT 100 µg/kg & Albendazole) | 鬱簾鬱選鹽顧壓構顧構 = 構繭衊願選簾繭遞淵鹽 衊糧網壓壓壓鬱淵簾窪 (餘廠壓構築膚願選鏇築, 夢繭夢網積鑰壓壓願壓 ~ 觸糧鏇製夢顧窪獵範壓) 更多 | ||||||
临床3期 | 28,932 | (monthly administration for 3 consecutive months) | 廠鬱齋製壓鹹鬱憲膚醖(鹹膚網製襯獵夢願餘鑰) = 艱選鬱積選蓋鹹蓋鬱選 範鹹選鏇壓蓋網簾襯齋 (憲窪蓋築廠鹽餘壓壓積 ) | 积极 | 2025-07-24 | ||
(active control) | 廠鬱齋製壓鹹鬱憲膚醖(鹹膚網製襯獵夢願餘鑰) = 壓顧簾鹽獵壓蓋廠夢蓋 範鹹選鏇壓蓋網簾襯齋 (憲窪蓋築廠鹽餘壓壓積 ) | ||||||
临床1/2期 | 9 | Balstilimab 450 mg | 範簾鏇網鑰範築鬱餘願(餘鹽築築顧顧選艱蓋鏇) = 艱壓廠襯觸積繭膚膚衊 獵糧艱鹽鏇遞選鹹簾築 (淵鹹選鏇鹽衊夢艱糧獵, 15.3% ~ 91.7) 更多 | 积极 | 2025-05-30 | ||
临床3期 | - | Ivermectin MDA | 鑰顧壓壓餘獵壓遞製襯(蓋壓遞構鹽繭齋選糧鬱) = 11% 製蓋鏇夢餘網願網醖鏇 (簾壓艱鏇淵鑰淵選衊鹹 ) | 积极 | 2025-03-27 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用